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Relationship of altered sodium transport to body mass and left
ventricular hypertrophy in essential hypertensives. L. Garcés, E. Garrigos,
R. Paya, I. Torregrosa, E. Parra, E. Bea, J. Sanchis, J.M. Escobedo, and A.
Perez, Servicio de Nefrologia, Hospital General, Valencia, Spain. This study
evaluated the Na transport mechanism with kinetic studies (kM and V,,,ax)
in erythrocytes of a control healthy population (35 subjects) aged 21 to 72(X = 42.2 2.4 years) and 37 hypertensive patients aged 19 to 72 (X =
50 1.9 years). We performed echocardiography (M mode and bidimen-
sional) to assess left ventricular mass (LVM) and LVM index (LVMI). We
also performed a complete clinical examination with Quetelet's body mass
index and basic blood chemistry. We applied the Hanes-Wolf equation to
the kinetic biological measurements. LVM was higher (P < 0.001) in the
hypertensives (223.7 15)compared with the control group (136.6 6.6).
Those more affected were the hypertensive Na-K ATPase (—) (P < 0.05)
than the contratransport (+) (P < 0.01). When the LVM values were
corrected for body surface, these differences with the controls (LVMI =
77.4 3.5) were more marked, the LVMI being 109.2 9.5 in patients
pump (—) (P < 0.001) and 121.1 10 in those contratransport (+) (P <
0.01). Patients contratransport (+) had a higher body mass index than
those who were pump (—) (P < 0.01). Heart involvement was not
significant in patients who were cotransport Na-K (—), passive permeabil-
ity (+) and those where no anomaly could be detected. Conclusions:
Hypertensives with a lowered affinity for the internal Na, according to the
Na-K ATPase pump, and those with a higher Vms.,, for the contratransport
Na-Li, have a higher myocardial involvement.
Sodium transport anomalies and metabolic alterations in essential
hypertensives. L. Garcés, E. Garrigos, J.M. Escobedo, M Gimenez, E. Bea,
I. Torregrosa, E. Pan-a, E. Vida4 and A. Perez, Servicio de Nefrologia,
Hospital General, Valencia, Spain. The aim of this study was to determine
the renal and metabolic alterations associated with the hypertensive
syndrome in a group of hypertensive subjects considered both globally and
as members of different subpopulations according to their altered Na
transmembrane transport mechanism, as assessed with kinetics studies
(km and Vms,,). These results were compared with a normotensive control
group. There were 35 control subjects (18 F and 17 M) aged 21 to 72 years(X 42 2.4) with 37 patients in the hypertensive group (24 F and 13 M)
aged 19 to 72 years (X = 50 1.9): 11 of these were pump (—), 6
cotransport (—), 11 contratransport (+), 40 passive permeability (+), and
5 had no detected anomaly. All patients had a similar hypertensive course
except for those with no anomalies detected whose course was longer
(P < 0.05) and had higher serum uric acid values (P < 0.001) due to a
greater vascular involvement. The renal parameters studied (creatinine
clearance, 24 hour urinary Na excretion and Na fractional excretion) were
similar in both hypertensives and controls. Lipid metabolism differed
between both groups, the hypertensives having higher cholesterol (Chol),
triglycerides (Tn) and apo B cholesterol (apoB) levels (P < 0.001),
affecting patients pump (—), contratransport (+) (P < 0.001, higher Chol
for both groups), pump (—) (higher apoB P < 0.001) and contratransport(+) (higher Tn P < 0.001).
Relationship of familiar aggregation and HLA system to Na transmem-
brane transport anomalies in a hypertensive population. L. Garcés, E.
Garrigos, N. Puig, E. Pan-a, E. Bea, I. Ton'egrosa, M. Gimenez, J. Villaro,
and A. Perez, Servicio Nefrologia, Hospital General, Valencia, Spain.
Epidemiological studies have demonstrated a familiar aggregation and an
association to specific HLA antigens in the hypertensive population. The
aim of this study was to assess these genetic aspects in the hypertensive
population of our area. We determined the HLA antigens in 35 normo-
tensive controls and in 37 hypertensive patients. Later we added data from
250 blood donors to the normotensive control group, selecting the class I
antigens with a higher relative risk and comparing them with those of the
hypertensive patients subdivided according to their detected Na trans-
membrane transport anomaly. We used Wolf s test of relative risk and
Fisher's test to assess statistical significance. There is a significant familiar
agregation for the hypertensives (P < 0.001). Subpopulations pump (—),
cotransport (—) and contratransport (+) had a higher presence of family
history of hypertension (P < 0.001 all subgroups), being lower for those
passive permeability (+) and without significance when no anomaly could
be found. Patients pump (—) had a higher relative incidence of HLA B 21
(P < 0.05). The relative risk for antigen B15 in patients cotransport (—),
HLA B 8 in those contratransport (+) and passive permeability (+) was
> 1. Conclusions: There is a basis to recognize a genetic component in the
hypertensive syndrome, even considering the heterogenicity of the pa-
tients.
Quinapril ACE inhibition effects on the adrenergic transmission pa-
rameters in moderate essential hypertension. M Vallés, M Matas, f.
Bronsoms, G. Maté, P. Torguet, and J.M Mauri, Nephrology Service,
Hospital "Dr. Josep Trueta", Girona, Spain. ACE inhibition effects on the
renin-angiotensin system (RAS) are well-known, even though the rela-
tionships between RAS and the adrenergic system (AS) in human HT are
incompletely understood. In order to analyze this, the changes in the
vascular reactivity after ACE inhibition with quinapril have been studied.
Eighteen cases with moderate HT have been studied. Three weeks before
the start a sodium restricted diet alone was indicated. A monotherapy with
quinapril in a monodose regime was indicated after and maintained for 4
months. Doses were adjusted until a stable normotension was achieved.
Hormonal, norepinephrine (NE), epinephrine (B), aldosterone (A), an-
giotensin II (AT), biochemical and 24 hours blood pressure ambulatory
monitoring and vascular reactivity studies were performed before and
after quinapril treatment. Vascular reactivity to infused NE and AT was
assessed in terms of pressor dose 20 (PD2O) for both systolic and diastolic
basal values. Quinapril effectively reduced both the pretreatment S and D
tensional values. Consequently, quinapril R and A levels increased.
Coincidently, NE and E plasma levels were reduced. The PD2O for both
NE and AT was lower when compared with the pretreatment estimations,
but in spite of the trend statistical significance could not be attained. These
data are consistent with effective quinapril therapy, mediated by both
R-AT and adrenergic systems blockage. The associated increase in the
vascular reactivity might suggest up-regulation of AT and NE vascular wall
receptor.
Hypertensive nephrosclerosis (HN): Clinical meaning and prognostic
factors. R. MarIn, E. Gonzalez, F. Ferndndez-Vega, E. Gómez, M. Gorostidi,
and J. Alvarez, Division of Nephrology, Hospital Covadonga, Oviedo, Spain.
We have studied the natural history of HN and its eventual relationship
with cardiovascular risk factors. Among 214 patients diagnosed with
essential hypertension and HN, from January 1988 to December 1993,
were selected 87 based on the following criteria: symmetrical kidneys,
serum creatinine  1.5 mg%, urinary protein < 2 glday, absence of
hematuria, and glycemia < 120 mg%. The control group was formed by
693 patients with essential hypertension. Cardiovascular complications
appeared in 41% of HN patients, against 9% in the control group (P <
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0.001). No difference was found in the incidence of smoking, ventricular
hypertrophy, or HDL-cholesterol. Patients with HN were older (69 9 vs.
49 13, P < 0.001), had greater serum cholesterol levels (232 45 vs. 222
44, P < 0.05), higher triglycerides (146 57 vs. 120 66, P < 0.001),
higher uric acid (7.2 1.5 vs. 5.3 1.5, P < 0.001), and a greater male
preponderance (59% vs. 40%, P < 0.001). However, their mean pressures
(112.7 12 vs. 120.4 15, P < 0.001), and body mass index (27.3 3 vs.
29.8 4, P < 0.001) were lower. HN is frequently related to other
cardiovascular complications and appears mainly in older aged men and is
not related with higher levels of arterial pressure nor smoking, but is
associated with dislypidemia.
Epidemiology study on arterial hypertension and renal function (Laen-
nec '93 trial). R. MarIn, and L.M Ruilope, by Cooperative Workshop of
Spanish Nephrology Society and Spanish Hypertension League, Spain.
Objectives: The assessment of the frequency of renal insufficiency in
patients with essential hypertension controlled by primaly medical atten-
tion. Methods: By means of a transversal, observational and descriptive
study we have reviewed 6,609 protocols supplied by 825 family physicians
in throughout Spain. A total of 5,903 patients fulfilled the inclusion
criteria: high blood pressure (BP) of essential etiology, aged more than 40
years old, and absence of renal disease. The following parameters were
analyzed: hypertension diagnostic date, systolic and diastolic BP, serum
creatinine (Scr) and clearance of creatinine (Car) according to Cockcroft
and Gault equation, total, HDL and LDL serum cholesterol and triglyc-
erides. Results: The mean age of the group was 62 years (40—94 range),
with 59% being women. An average time of 53 months had elapsed since
hypertension was diagnosed. The BP mean was of 155 18/90 10 mm
Hg. The Sr mean was 1.0 0.4 mg/dl and the Cr 85 29 mI/mm, and
12.3% had Sr > of 1.2 mg/dl. The patients with 5Cr > 1.2 mgldl were
older (65 11 vs. 61 10 years, P < 0.001), their hypertension was also
of longer duration (86 74 vs. 68 65 months), and there was a greater
male preponderance (60% vs. 40%, P < 0.001). Moreover, they presented
higher levels of systolic (160 21 vs. 155 18 mm Hg, P < 0.001) and
diastolic BP (92 11 vs. 90.5 10mm Hg, P < 0.001) and also, of total
serum cholesterol (244 43 vs. 235 43 mg/dl, P < 0.001), LDL-
cholesterol (160 37 vs. 152 41 mg/dl, P < 0.001), triglycerides, (165
81 vs. 143 69 mg/dl, P < 0.001) and lower level of HDL-cholesterol (48
12 vs. 53 15 mg/dl, P < 0.001). The group with BP> 140/90 mm Hg
had higher levels of 5Cr (1.007 0.4 vs. 0.98 0.3 mg/dl, P < 0.001), total
serum cholesterol (238 41 vs. 230 49 mg/dl, P < 0.001) and
triglycerides (149 73 vs. 135 64 mg/dl, P < 0.001). Conclusions: (1) A
considerable proportion of patients with essential hypertension had levels
of 5Cr compatible with renal insufficiency. (2) These patients were older,
mainly men, they had higher levels of BP and greater rates of dyslipidemia.
Continuous monitoring of ambulatory blood pressure (CMABP) in
hypertension undergoing hemodialysis. N.S. Jabaty, E. Hemandez, M.
Anvnz, L. Sanchez, A. Mendiluce, J. Nuflez, and J. Bustamante, Hospital
Universitario, Servicio de Nefrologia, Valladolid, Spain. Pre- and post-
dialysis blood pressure (BP) in hemodialysis (HD) patients does not
predict interdialysis BP. Increase in BP before HD, abnormal circadian
rhythm and absent of BP falling during sleep were reported. The purpose
of this study was to confirm the increase of predialysis BP, its relationship
with weight gain and the absence of circadian rhythm. Eleven hypertensive
patients undergoing HD were studied, 8 females and 3 males, aged 45.6
13.1 years, (range 26—68 years). CMABP was carried out (24 hours before
and all during HD procedure) with an automatic non-invading instrument
(Spacelab 90902); blood chemistry and weight gain were also considered.
Results: We found significantly increased systolic (P < 0.05), diastolic
(P < 0.01) and mean BP (P < 0.05) in the two hour period before HD,
compared with the 24 hour and interdialysis BP period. No relationship
was found with weight gain or blood hemoglobin. No statistical differences
were found between day and night BP. Conclusion: Increased BP two
hours before dialysis was detected and there was no correlation with
weight gain. Abnormal circadian rhythm and absence of increased BP
during sleep was seen in our HD patients.
Significance of functional tests in primary aldosteronism. MD. Albero,
F. Rivera, M.D. Arenas, A. Picd M. Mauri, J. Torralba, F. Picazo, L.A.
Jiménez, and J. Olivares, Servicios de Nefrologla, Endocrinologla y Hormo-
nas, Hospital Universitario de Alicante, Facultad Medicina (Dept. of Medi-
cina Interna), Alicante, Spain. Primary aldosteronism is clinically similar to
adenoma (A) and hyperplasia (H), but its patogenesis is different. We
have studied the variations of plasma renin activity and serum levels of
aldosterone after functional tests (orthostatism plus frusemide, saline
expansion, captopril test, ACTH stimulation, and cortisol profile) were
performed in 18 patients with well-proven primary aldosteronism (11 A
and 7 H) by TC, isotope tests or surgery. We did not find differences
between A and H in age, sex, target organ damage and levels of serum and
urine electrolytes. In all patients as a group we observed the following
significant results (by t-paired test): (i) decrease of aldosterone levels after
saline expansion; (ii) increase of aldosterone and cortisol levels after
ACTH stimulation; and (iii) decrease of plasma renin activity after
captopril test. Mean blood pressure was higher in A compared to H (126.
17 vs. 110 16 mm Hg, P = 0.04). When we evaluated separately the
response in A and H we found that the decrease of aldosterone after saline
expansion appeared only in H (initial: 493.4 340.2; final: 207.7 146.3
ng/dl, P = 0.01). The levels of aldosterone increased after ACTH
stimulation in A (initial: 698.5 652.6; final: 1295.7 1103 ng/ml, P =
0.01) but not in H. The ratio plasma renin activity/aldosterone after
captopril test decreased in A compared to H. Finally, cortisol levels
increased in both subgroups. We concluded that the responses to func-
tional tests are not similar in A compared to H, with decreased levels after
saline expansion in H and increased after ACTH stimulation in A. There
are probably different mechanisms of aldosterone synthesis and cellular
liberation in these forms of primary aldosteronism.
Relation between diastolic dysfunction and hyperinsulinemia in essen-
tial hypertension. Sensibility and specificity tests. F. Rivera, MC. Prados,
P. Bordes, M. Maun, M.D. Albero, J. Torralba, A. Ca,rión, M.D. Arenas, and
J. Olivares, Servicios de Nefrologia, Cardiologla y Hormonas, Hospital
General, Universitario de Alicante, Facultad Medicina (Dept. of Medicina
Interna), Alicante, Spain. Insulin resistance and secondary hyperinsuline-
mia are related to diastolic dysfunction in essential arterial hypertension.
We investigated global reliability of serum levels of glucose, insulin and
peptide-C after oral surcharge glucose test (75 g) for 120 minutes to
evaluate diastolic dysfunction. Sensibility and specificity tests of these
levels by Receiver Operator Characteristic Curves (ROC) at different cut
points were investigated. Simultaneously, echocardiography and pulsed
Doppler recordings of diastolic flow through the mitral valve were
performed. Peak velocities during early filling (E) and from atrial con-
traction (A) were measured. When E/A ratio was  1, diastolic dysfunc-
tion was considered (gold standard). The best parameter with more
surface under the curve was peptide-C, compared with insulin or glucose
serum levels. At different cut points, the best value was serum peptide-C:
5.4 ng/ml (sensibility: 66.6% and specificity: 81.3%; odds ratio: 8.6 and
confidence interval 1.04—71.5, P = 0.05). We concluded that serum levels
of peptide-C are useful to evaluate insulin resistance and its relationship
with diastolic dysfunction, with acceptable values of sensibility and spec-
ificity.
Hyperinsulinemia and diastolic dysfunction in essential hypertension.
MC. Prados, F. Rivera, P. Bordes, M Mauri, MD. Albero, J. Torralba, A.
Carrion, M.D. Arenas, and J. Olivares, Servicios de Nefrologla, Cardiologla y
Hormonas, Hospital General, Universitario de Alicante, Facultad Medicina
(Dept. Medicina Interna), Alicante, Spain. Insulin is a growth factor
implicated in the development of left ventricular hypertrophy in essential
arterial hypertension. In our experience, hypermnsulinemia and elevated
left ventricular mass in patients with essential hypertension were observed.
However, the relationship between hyperinsulinemia and diastolic dys-
function is largely unknown. We studied 23 patients with grade I—lI
hypertension (9 men, 14 women; mean age 48.1 9.2 years), treated with
different antihypertensive drugs, without having overt diabetes or being
overweight (BMI 25 1.7). Serum glucose, insulin and peptide-C after
oral surcharge glucose test (75 gr) at 0 and 120 minutes were measured.
Simultaneously, echocardiography and pulsed Doppler recordings of
diastolic flow through mitral valve were performed. Peak velocities during
early filling (E) and from atrial contraction (A) were measured. When EtA
ratio was  1 diastolic dysfunction was considered. The subgroup of
patients with diastolic dysfunction had levels of glucose, insulin and
peptide-C higher compared to the patients with normal diastolic function;
indeed, this difference was statistically significative in peptide-C levels at 0
and 120 minutes (2.42 0.89 vs. 1.67 0.58 and 5.93 1.13 vs. 4.89
0.88 nglml, respectively; P = 0.05). We did not find differences in sex or
BMI. However, the patients with diastolic dysfunction were older com-
pared with the remaining (53.7 3.9 vs. 45.6 9.9 years, P = 0.012). We
concluded that hyperinsulinemia (evaluated by serum levels of peptide-C)
and age are related to diastolic dysfunction in hypertensive cardiopathy.
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
C. Alamo, M Praga, J. Vara, E.G. Pan-a, A. Araque, J.M Morales, A. Ortiz,
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and J.L. Rodicio, Hospital 12 de Octubre, Madrid, Spain. Very few patients
with familial hypomagnesemia, hypercalciuria and nephrocalcinosis have
been described. Information about clinical course, familial studies, or
evolution after renal transplantation is very scant. We have studied 8
patients with this syndrome who belong to 5 different families. Age at
diagnosis was 15 7 years (5—25 years). Main clinical data were
polyuria-polydipsia (8 cases), ocular abnormalities (5), recurrent urinary
tract infections (5), and recurrent renal colics with Stone passage (2).
Bilateral nephrocalcinosis was observed in all cases. Every patient showed
hypomagnesemia (1.1 0.2 mg/dl) with inappropriately high urinary
magnesium (Mg) excretions (70 17 mg/day), Mg clearances (4.4 1.2
mI/mm) and Mg fractional excretions (16.2 7.1%). Hypercalciuria was
present in every case except in those with advanced renal insufficiency.
Serum parathormone levels were abnormally high. Serum calcium (Ca),
phosphorus and potassium, and urinary excretions of uric acid and oxalate
were normal. Neither chronic oral Mg administration nor thiazide diuret-
ics normalized serum Mg levels or urinary Ca excretions, respectively.
Follow-up has been 6 4.5 years. Renal function worsened in every case,
with 6 patients starting on chronic dialysis after 4.3 3.8 years. The
progression rate of renal insufficiency correlated with the severity of
nephrocalcinosis. Five patients have received a kidney graft; serum Mg
and urinary Ca have always been within normal values after transplanta-
tion. Twenty-six members of 4 of the affected families were studied: none
of them showed hypomagnesemia, renal insufficiency, or nephrocalcinosis.
However, 11 cases (42%) had hypercalciuria and 4 of them had presented
recurrent renal stones. Two family members had medullary sponge
kidneys. In conclusion, progression to renal insufficiency is common in this
syndrome; oral Mg and thiazide diuretics are ineffective to correct
abnormalities. After kidney graft, tubular handling of Mg and Ca was
normal. A striking incidence (42%) of hypercalciuria was found in the
familial study.
Markers of endothelial dysfunction in IgA nephropathy. E. Hemández,
M Praga, T. Toledo, B. Ortuno, A. Manrique, A. Araque, C. Alamo, andf.L.
Rodicio, Hospital 12 de Octubre, Madrid, Spain. Since mesangial cells
produce several vasoactive substances, endothelial dysfunction could have
a role in the progression of IgA nephropathy (IgAN). We have studied
plasma levels of von Willebrand factor (vWF), an indicator of endothelial
cell dysfunction, and other markers of endothelial damage in 18 patients
(37 11 years) with IgAN and normal renal function (GFR measured by
99TC-DTPA clearance >75 mI/mm) and in a control group of 12 healthy
subjects. Patients taking antihypertensive drugs they were withdrawn from
them 1 month before study. In IgAN patients, GFR was 114 26 mI/mm
(75—152), proteinuria 1.1 0.9 g/day (0—3.8), and blood pressure 135
25/87 12 mm Hg. IgAN patients had significantly higher levels of vWF
and serum uric acid than normal controls: 145 62% (74—352%) versus
81 24% (P < 0.001) and 7.1 1.8 versus 4.8 0.3 mg/dl (P < 0.001),
respectively. There were no differences in plasma endothelin (61.9 21 vs.
62.5 22 pg/mI) nor in serum cholesterol levels (218 44 vs. 190 25
mg/dl). In IgAN patients, vWF levels showed a significant positive
correlation with proteinuria (r 0.60), cholesterol (r 0.50) and uric acid(r = 0.50). In addition, proteinuria showed a significant positive correla-
tion with uric acid (r = 0.54) and cholesterol (r = 0.58). In conclu-
sion, patients with IgAN and normal renal function show increased lev-
els of vWF and uric acid. The correlation found between these markers
of endothelial dysfunction and proteinuria supports the participation of
endothelial damage in the progression of this disease.
Report of glomerulonephritis (GN) in Spain. 1993 data. Spanish
Registry of Glomendonephritis (REGN), Spain. As in previous years, during
1993 REGN has recorded the epidemiology of GN in Spain. Data of
kidney allograft were excluded. Data reported to REGN were composed
of: cases of primary GN (PGN) and secondary GN (SGN), each of them
subclassified in cases diagnosed according to renal biopsy or clinical basis.
Patients were classified according to their kidney histology features into 8
categories of PGN and 4 of SGN. Clinical features were recorded in 6
renal syndromes. Patients were classified as adults when they were 15 years
old and over, and as children if they were younger. Seventy referring
hospitals (60 adults' and 10 childrens') reported 1,917 cases (76.5% adults,
71% PGN) diagnosed of GN on a clinical basis, and 1,417 of them were
biopsied. PGN (N = 1,362)/ON were more frequent in children than in
adults (80.4% vs. 68.1%, respectively). IgA GN was the first cause of PGN
in adults and in children, but with different frequencies. In the former
group IgA ON, membranous ON and membranoproliferative GN were
more prevalent than in the latter (24.7% vs. 18.6%; 13.5% vs. 5.2%, and
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8% vs. 3.4%, respectively); however, in children the prevalence of minimal
change disease and focal hyalinosis was higher compared to adults (17.4%
vs. 9.8%; 14% vs. 12.6%, respectively). There was a prevalence of lupus
nephritis and renal amyloidosis in adults compared to children (34.1% vs.
15.2%; 14.9% vs. 1.6%, respectively); however, in children vasculitis was
more frequent than in adults (42.3% vs. 23.7%). The prevalence of
membranoproliferative GN in the north of Spain in adults is more
frequent than in the rest of the country; there were no other geographical
differences in the prevalence of remaining ON. Nephrotic syndrome
followed by persisting asymptomatic urinary abnormalities (proteinuria
and hematuria) were the most frequent clinical syndromes in all cases;
however, bouts of macroscopic hematuria were more frequent in children
compared to adults. The clinical syndromes at the time of renal biopsy in
IgA ON were different; in adults urinary abnormalities were the most
frequent syndromes and in children it was macroscopic hematuria. The
prevalence of arterial hypertension was higher in adults than in children
(31% vs. 8.5%). Comparing the total number of biopsied GN in the last 3
years we found that membranoproliferative GN had a slight increase in
1993, suggesting that the descending curve observed over the past decade
is not confirmed. Extracapillary ON shows a tendency to decrease, without
significant variation in the prevalence of the remaining ON.
Captopril-induced hemodynamic changes and their influence on pro-
teinuria. I. Zamora, J. Simon, S. Mendizaba4 F. Martinez, and L. Perez,
Pediatric Nephrology Unit, Children s Hospital Ia Fe, Valencia, Spain. The
antiproteinuric effect of angiotensin converting enzyme (ACE) inhibitors
has been widely demonstrated, although there is little experience in a
pediatric series. The aim of our study was to evaluate the antiproteinuric
effect of captopril in children with glomerulopathies and try to correlate it
with the intrarenal hemodynamic changes induced by the drug. Captopril
(1 mg/kg/day) was given during 6 months to 32 children with diverse
glomerulopathies but without nephrotic syndrome, all with proteinuria
(>4 mg/m2/hr) persistent over 6 months, glomerular filtration rate over 80
ml/min/1.73 m2, and an absence of hypoalbummnemia. Only 2 were
moderately hypertensive. Prior to the start and at the end of the treatment
period the filtration fraction (FF) was explored by means of inulin and
PAH clearances, and plasma renin activity (PRA) was measured. Creati-
nine clearance, 24 hour protein excretion (Uprot), protein/creatinine index
(Prot/Cr), leukocyte count, serum potassium and cholesterol, were all
determined during the treatment period. Results: The baseline parame-
ters in paired series are compared with the average values under treatment
with captopril: 133 versus 131 (NS); Ui,rot 32.7 versus 23 (P < 0.002),
Prot/Cr 1.23 versus 0.9 (P < 0.002). Captopril withdrawal was followed by
an increase of proteinuria to previous levels. A PRA increment (4.6 vs.
10.7; P < 0.005) and a FF decrease (0.22 vs. 0.20; P < 0.02) were
maintained under captopril treatment. The antiproteinuric effect appears
stronger in patients with higher baseline FF, suggesting that this is carried
out through a decrease in hyperfiltration induced by intrarenal hemody-
namic changes.
Transfemoral renal biopsy (TFRB) with forceps: Initial experience. C.
Vdzquez, J.I. Bilbao, F..!. Lavilla, F. Idoate, M. Martin, J. Buades, N. Garcia,
P. Errast4 and A. Purroy, Clinica Universitaria de Navarra, Pamplona,
Spain. Percutaneous renal biopsy (PRB) is contraindicated in patients with
severe bleeding disorders, morbid obesity, uncontrolled hypertension,
chronic respiratory insufficiency, solitary kidney, or in those unable to
collaborate. Traditionally, other more invasive methods had been used but
are still inapplicable in some of them. In 1990, a modification of the
transjugular liver biopsy was described as a suitable alternative to tran-
sjugular right kidney biopsy. We present the preliminary results using a
different approach, inspired from a recent report of liver biopsy, that
includes both the use of a flexible forceps and the femoral route. The
procedure is performed under local anesthesia and consists of the
advancement of a 7 Fr forceps through a long sheath, in either the right or
left femoral vein to the selected kidney (either right or left, or even a
graft). After placing it as distal as possible, into a small peripheral cortical
vein, the jaws are opened and wedged into the renal parenchyma and
several samples are obtained (usually 4 to 6). Sixteen renal biopsies were
performed with this new technique in 13 patients. Patients were referred
because of: cirrhosis with severe clotting disorders in 6, severe chronic
respiratory insufficiency in 2, morbid obesity plus failures to previous PRB
in 1, and a solitary left kidney in 1. In 7 cases other vascular procedures
apart from TFRB were performed: liver biopsy in 2, splenic embolization
in 2, direct portography post-TIPS in 1, TIPS in 1, and chemo-emboliza-
tion of a 4 cm hepatocellular carcinoma in 1. Renal tissue was obtained in
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15/16 procedures (93.7%) and glomeruli in 14/16 (87.5%). Mean number
of glomeruli per biopsy was 12.6 (0—39). Only minor complications
occurred in 2 patients (transient macroscopic hematuria). Transvenous
renal biopsy should be considered when other accesses are contraindi-
cated. The femoral approach allows other vascular procedures to be
performed at the same time and is still feasible in most anatomical
conditions (solitary left kidney, grafts, etc.). TFRB is a safe technique for
obtaining renal samples in high-risk patients, and the effectiveness (ade-
quacy of size sample), although worse than that obtained with the
percutaneous approach, is better than that reported with other transvas-
cular techniques.
Cardiac features in adult polycystic renal disease (APRD). M. Alcalá, .J.
Payán, G. Silgado, R. Mijares, R. Almaraz, A. Castro, D. Torán, J. C. Vargas,
and P. Gómez, Department of Nephrology and Cardiology, Hospital of SAS,
Jerez, Spain. APRD is often accompanied by extrarenal features. We have
conducted a comparative M-mode, bidimensional, and Doppler echocar-
dioigraphic study in 60 patients with APRD to test cardiac abnormalities
(group I) in 51 first-grade relatives (group II) and 52 healthy control
subjects (group III). The following parameters were analyzed: systolic and
diastolic ventricular diameters (SVD and DVD, respectively), aortic root
diameter (ARD), aortic regurgitation (AR), left ventricular mass (LVM),
mitral prolapse (MP), mitral regurgitation (MR), and tricuspid prolapse
and regurgitation (TP and TR, respectively). These variables were corre-
lated with renal function, time of evolution of APRD, and arterial
pressure. When compared with control group, groups I and II showed a
greater incidence of TR (10 and 7.7 vs. 0%, P < 0.05). MP was found in
6.7% and MR in 8.3% among patients with APRD, at a frequency which
was greater than that seen in the other groups (P < 0.05). The patients'
ARD (33 + 4.4 mm) was greater than that seen in group 11(29.7 + 3) and
group III (29.7 + 3.5) (P < 0.05). The LVM was significantly greater in
patients than in groups II and III (P < 0.01). Conclusions: (1) The
incidence of cardiac valve abnormalities is increased in first-grade relatives
of patients with APRD without renal cysts. (2) There is a high frequency
of cardiac valve abnormalities and increased LVM in patients with APRD,
the latter probably associated with concomitant arterial hypertension.
Incidence of hepatitis C virus antibodies (HCV-Abs) in glomerular
pathology. J. Esteban, E. Armada, A. Otero, C.H. Cristal, Hospital Pihor,
Orense, Spain. The association of HCV-Abs with membranous and
membranoproliferative glomerulonephritis (the latter usually with cryo-
globulinemia) has recently been reported. The aim of this study was to
evaluate the HCV-Abs incidence in patients with glomerular pathology
biopsied in our center during the last 4 years. From a total of 61 patients,
6 died and 15 could not be found; the other 40 patients (16 females, 24
males; aged 48.7 17.4 years) were tested for the detection of HB5Ag,
HCV-Abs (ETA, LIA III) and the positives for PCR (RNA). The
pathological analysis showed: 8 HSFG, 5 LHM, 5 MGN, 10 IgA GN, 3
MPGN, 3 RPGN, 1 HTA, 2 LES, and 3 other. One patient was HBsAg
positive (2.5%), 3 were HCV-Abs positives (7.5%), and 2 of these were
PCR+. Their features are shown in the Table.
Patient 1 Patient 2 Patient 3
Age/sex 70/F 44/M 31/M
Urea/Crp 80/1.3 60/1.0 65/2 mg/dl
C3/C4 69/8 55/13 129/34 mg/dl
Cryoglobulinemia (—) (—) (—)
Proteinuria 5 2 4 g/24 hr
Hematuria micro micro micro
ALT/AST 60/50 41/46 60/65 U/liter
PCR(RNA) (+) (+) (—)
Pathology MPGN MPGN IgA GN
In conclusion, the HCV-Abs incidence in our population with glomerular
pathology is high, greater than the hepatitis B incidence. The research of
HCV-Abs should be included in the protocol for studying glomerulopa-
thies.
Histological renal changes in IDDM patients with normoalbuminuria
and normal renal function. f.M. Maui-i, M. Vallés, W Ricart, J.M. Fernán-
dez-Real, J. Bronsoms, G. Maté, M. Matas, P. Torguet, and L. Bernadó,
Nephrology Service, Endocrinology Service, Pathology Service, Hospital "Dr.
Josep Trueta," Girona, Spain. Microalbuminuria (MA) is currently a
recognized marker of incipient diabetic nephropathy, as well as a valuable
prognostic indicator of its progression in IDDM. Changes in glomerular
and interstitial structure have been detected in microalbuminuric patients,
but these changes may also be present in the absence of MA. The aim of
this study was to characterize the renal histology in normoalbuminuric
(NA) and microalbuminuric IDDM patients. Patients with IDDM diag-
nosed according to ADA criteria more than 5 years ago or with MA were
studied consecutively. Those patients with decreased renal function (iso-
topically evaluated) were excluded. Urine albumin excretion (UAE) in
24-hour collected urine was evaluated at least twice. Mesangial fraction
(MF) and interstitial expansion (El) were morphometrically assessed by
optic microscopy. Quantitation studies on cadaveric donor kidneys were
used as controls. Thirty-six IDDM patients (19 males, 17 females, mean
age 32.4 9.6 years) were selected. Sixteen patients were NA (group I)
and 20 had MA (group II). Age, sex, age at diagnosis, and time from
IDDM diagnosis were similar in the 2 groups. Histological structures were
abnormal in both groups: MF was 0.239 0.06 (group I), 0.274 0.04
(group II), and 0.124 0.05 (control group, P < 0.001 between group I
and II vs. control); IE were 24.1 12.2 (group I), 24.6 10 (group II), and
13.7 3.2 (control, P < 0.001 for comparison between group II vs.
control, and P = 0.02 between group I vs. control). MF from group II
patients, but not IE, was significantively greater that those from group I
patients (P = 0.019). UAE was not correlated to MF or IE in either group.
Histological changes can be found in IDDM patients diagnosed more than
5 years ago, with NA and normal renal function. Prospective follow-up of
these patients will determine if these histological changes are predictive
for the progression to an established diabetic nephropathy.
Renal morphology in IDDM patients with normal and high glomerular
filtration rate. M Vallés, f.M Maui-i, W. Ricart, J.M. Fernandez-Real, J.
Bronsoms, G. Maté, M. Matas, P. Torguet, and L. Bernadó, Nephrology
Service, Endocrinology Service, and Pathology Service, Hospital "Dr. Josep
Trueta," Girona, Spain. Normoalbuminuric (NA) or microalbuminuric
(MA) IDDM patients usually show either high (HGFR) or normal
(NGFR) GFR. In both conditions morphological changes may be ob-
served, although morphological and functional correlations remain poorly
defined. The aim of this study was to analyze the relationship between
morphometric and functional renal parameters. Thirty-six IDDM patients
(19 males and 17 females) diagnosed more than 5 years ago or with MA
have been studied. GFR and renal plasma flow (RPF) were isotopically
evaluated. Mesangial fraction (MF) and interstitial expansion (IE) were
morphometrically assessed by optic microscopy. NGFR was found in 22
cases. HGFR was seen in 14 cases. Any correlation between morpholog-
ical and functional data was found when all 36 cases were evaluated. In
male patients MF and IE were significantly higher in NGFR than in
HGFR (P = 0.016 and P = 0.021 respectively), and there was a highly
negative correlation between GFR and MF (r =
—0.78, P < 0.001),
between GFR and IE (r =
—0.62, P < 0.01), between RPF and MF (r =
—0.74, P < 0.01), and between RPF and IE (r = —0.59, P < 0.01). Our
results suggest the possibility of a sex dependent difference in the
morphofunctional correlations. The finding of more pronounced morpho-
logical changes in NGFR patients might question the classical relationship
between anatomic and functional renal parameters.
Prevalence of infection by hepatitis C virus (HCV) in patients with
primary glomerulonephritis. Association with focal and segmental gb-
merubosclerosis. J. MartInez-Ara, J.L. Miguel, M.L. Picazo, R. MartInez-
Zapico, C. Jiménez-MartIn, and C. Ririón, Hospital La Paz, Madrid, Spain.
The histological patterns more frequently described of glomerular lesions
associated with HCV infection are type I membranoproliferative glomer-
ulonephritis, with or without essential mixed cryoglobulinemia, and mem-
branous nephropathy. We investigated the prevalence of HCV infection in
83 primary glomerulonephritis (PGN) patients and we found anti-VHC
antibodies (Ab) (ELISA; confirmed by RIBA) (HCV+) in 6 patients(7.2%), which was significantly higher than in the normal population
(0.8%) (P < 0.05, x2). One of these patients was excluded because of
associated VIH infection. In the remaining 5 HCV+ patients, we also
found Ab anti-HCV of IgG class (ELISA) in 2. Viral RNA (PCR) was
negative in all cases. No patients showed VHB infection or cryoglobuline-
mia. Four patients were males, with a mean age of 48 years at entry. Two
patients had risk factors for the HCV infection (hemophilia A and
transfusion) and another had a high familial incidence of hepatopathy. All
patients showed clinical evidence of chronic liver disease, with abnormal
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values of serum hepatic transaminases, fluctuating in 4 cases and perma-
nent in the fifth. This patient was the only one on whom a liver biopsy was
performed (chronic active hepatitis). The initial clinical symptoms were
nephrotic syndrome (NS) in 2, nephrotic range proteinuria (NRP) in 1,
and asymptomatic proteinuria and hematuria (APH) in the remaining 2
patients. All had normal renal function. Seven renal biopsies were
performed in the 5 patients. Focal segmental glomeruloscierosis (FSGS)
was diagnosed in all instances. In 4 patients we identified the classical form
of FSGS (2 with indeterminate location of scar, 1 periferical, and another
hilar), and the fifth had the glomerular "tip" lesion. In the 2 patients with
a previous biopsy 1 was preceded with mesangial proliferative glomerulo-
nephritis, and in the other with minimal changes. The immunofluores-
cence study showed 1gM deposits in all cases. Four patients were treated
with several courses of cyclophosphamide and/or steroids. At the end of
follow-up (mean: 118 months), 1 patient showed NS, another NRP, 2
APH, and the fifth was in complete remission. Two patients, 1 with
mesangial proliferation associated and another with hilar pattern of scar,
showed a moderate renal insufficiency (creatinine clearance of 62 and 50
mi/mm, respectively). In summary: (1) We have found a high prevalence
of HCV infection in primary glomerulonephritis, without cryoglobuline-
mia; (2) In all HCV+ cases, a focal segmental glomeruloscierosis was
present; (3) The nephropathy showed a relatively benign clinical course.
Is cyclosporin-A (CsA) the treatment for the steroid resistant idio-
pathic nephrotic syndrome (SR-INS)? V. Valverde, E. Bosque, Nefrologla,
Hospital de Elda, Alicante, Spain. We carried out a retrospective review of
the evolution of 8 adult patients (ages: 39 23 years) with a diagnosis of
SR-INS, after 36 months on CsA. The histological diagnosis showed 5
patients with focal segmental sclerosis, 2 with proliferative mesangial 1gM,
and 1 with minimal change disease. All of them underwent at least 8 weeks
of corticotherapy (1.5—2 mg/kg/day) with no significant decrease in pro-
teinuria. In three of them cyclophosphamide (2 mg/kg/day) was used
afterwards, and the results were likewise negative. All of them were
administered CsA (3—S mg/kg/day) and they maintained a blood level of
CsA between 90 and 150. A progressive reduction in proteinuria from 14.2
5.7 to a number lower than 1 g/day was observed, showing an increase
in serum albumin (from 1.56 0.9 to 3.97 0.7 g/dl), whereas the rest of
the parameters were within normal limits. Three patients received costi-
costeroids during the first months concomitantly, although sometimes
discontinuously. During the time the patients were under observation,
which was more than 5 years, CsA was tolerated well and no relevant side
effects were observed: initial blood pressure was 120/75 mm Hg and final
was 110/70; initial Cr 1.17 0.3 and final 1.16 0.5 mg/dl; initial uric acid
8.87 0.96 and final 6.76 0.83. The attempts to eliminate CsA showed
an exacerbation in proteinuria which diminished when the previous doses
was reestablished. Therefore, we might say that CsA is the most appro-
priate treatment for SR-INS, provoking its remission and causing no
relevant side effects. CsA dependency seems to be the main complication.
Strict patient care is essential.
Induction of collagen fibrogenesis in vitro. Comparative study of the
effects of endothelin and cyclosporin A. F. O'Valle, J.L. LOpez-Hidalgo, F.
Revelles, C. Ram frez, MA Lucena, M. Aguilar-Peña, D. Aguilar-Pena, and
R Garcia del Moral, Department of Pathology, University Hospital of
Granada, Granada, Spain. Background: Endothelin (ET), in addition to
acting as a potent vasoconstrictor, is involved in cyclosporin A (CsA)-
mediated nephrotoxicity. The secretion of ET by fibroblasts, and its ability
to induce collagen synthesis, have been reported recently. One of the
actions attributed to CsA is its ability to induce fibrogenesis. As a direct
factor in fibrogenesis, CsA is controversial, and it has been postulated that
the appearance of fibrosi in the kidney is mediated by other substances
(such as ET) which, once released from the tubule and/or interstitia,
stimulate the synthesis of collagen by renal interstitial fibroblasts. Design:
We studied ET secretion after pharmacological stimulation with CsA (0.5
and 1 j.tg/ml) in the VERO fibroblast cell line, and analyzed the fibrogenic
capacity of ET (2.5 ng/ml). Material and methods: ET in VERO cells was
quantified by flow cytometry (Ortho Cytoron Absolute), using indirect
immunofluorescence with monoclonal antibodies to type N ET (which
recognize active ET and big-ET), and to type C FT (which recognize the
terminal C fraction of active ET). In supernatants of cell cultures we used
radioimmunoassay (total ET and ET 1—21) after 3, 6, 12, 24 and 48 hours,
and 7 and 60 days. The induction of fibrosi by FT was assessed by
[3H]proline uptake and the formation of type IV collagen after 2 and 7
days. Results: There was no difference in ET secretion after incubation
with CsA during the first 48 hours of culture. However, after 60 days, there
was an increase in total ET secretion (2888 pg/mI) and active ET secretion
(536 pg/mI), in comparison with control cultures (total ET 1992 pg/mi;
active ET 286.9 pg/mI; (P < 0.05, Student's t-test). Incubation with FT led
to an increase in [3H]proline uptake (treated 3850 dpm; control 2402 dpm;
(P < 0.001, Student's t-test), and to increased synthesis of type IV collagen
after 7 days. Conclusions: VERO cells synthesize and secrete active FT
under basal conditions, and synthesis is increased after prolonged incuba-
tion with CsA. The presence of ET in the culture medium induces the
early synthesis of collagen.
Adhesion molecules in glomerulonephritis. M. T. Medina-Cano, M
GOmez-Morales, J. Alonso, M Andüjar, C. Ram frez, E. Vergara, R. Carvia,
S. Cerezo, and R. Garcia del Moral, Department of Pathology and Nephrol-
ogy Service, University Hospital of Granada, Granada, Spain. Adhesion
molecules are fundamental in the regulation of cell differentiation,
localization of inflammation, and the immune response. This study was
designed to shed light on the role of these molecules in the pathogenesis
of inflammatory kidney disease, and to point the way to new treatment
options in glomerulonephritis (GN). Material and methods: The alkaline
phosphatase-anti-alkaline phosphatase technique with double incubation
on frozen slides was used to study the expression of the adhesion
molecules ELAM-1, VCAM-1, and ICAM-1 in 60 specimens of GN.
Expression was evaluated in the Bowman capsule, glomerular tufts,
tubules, endothelia of vessels of different diameters, and inflammatory
infiltrate. Results: In comparison with the findings in control specimens,
ELAM and VCAM expression was significantly decreased in the Bowman
capsule (P < 0.01), and increased in glomerular tufts (P < 0.05) in
specimens from patients with kidney disease. In GN samples, VCAM was
overexpressed in vascular endothelia (P < 0.05), and ICAM expression
was reduced in glomerular tufts (P < 0.01). In idiopathic GN, expression
of the ELAM molecule in the glomerular and interstitial vascular endo-
thelia was significantly higher in comparison than in secondary GN
[vasculitis and systemic lupus erythematosus (SLE), (P < 0.05)). Discrimi-
nant analysis yielded an equation that distinguished between primary and
secondary GN (75% sensitivity) on the basis of VCAM expression in the
inflammatory infiltrate (primary GN: —0.8878 + VPIC X 1.03846; sec-
ondary GN: —2.85 + VPIC >< 3.46; VPIC = VCAM-positive inflamma-
tory cells). When the cases of GN were divided into cases showing high
and low aggressiveness, the former subset showed higher expression of
ICAM in tubules (P < 0.05), and higher expression of VCAM in Bowman
capsules (P < 0.01) and peritubular capillaries (P < 0.05). Conclusions:(1) Decreased expression of ELAM and VCAM in the Bowman capsule,
and overexpression in glomerular tufts, together with decreased expres-
sion of ICAM in glomerular tufts, were the major differences between GN
and control specimens. (2) Although there was no characteristic pattern of
expression of these three molecules in each subtype of GN, further study
of these molecules may be of interest for prognostic purposes, to assess the
degree of aggressiveness, or to shed light on the pathogenic mechanisms
of GN. (All P values refer to results with Mann-Whitney tests).
Differentiation antigens and fibrosis in non-neoplastic kidney disease.
MT Medina-Cano, F. O'Valle, N. Navarro, P. Lardelli, M. Anddjar, T.
Caballero, MJ. Garcia-Chicano, A. Novas, and M Gómez-Morales, Depart-
ment of Pathology and Nephrology Service, University Hospital of Granada,
Granada, Spain. Tubulointerstitial lesions have become more frequent in
assessments of renal biopsies. We attempted to determine the prognostic
value of certain signs of tubular and interstitial damage. Material and
methods: Interstitial fibrosis was quantified with a digital image analysis
system (Visilog 3.6), and the expression of renal differentiation markers
[vimentin, epithelial membrane antigen (EMA) and CDI5], and of type
IV collagen, was assessed semiquantitatively by three independent observ-
ers. We analyzed 96 renal biopsies with the avidin-biotin-peroxidase
method. The parameters were correlated with clinical and histological
findings of documented prognostic value, and with the different subpopu-
lations of leukocytes. Results: Interstitial fibrosis, expressed in .rm2, was
significantly greater in biopsies with kidney disease than in control
specimens (Mann-Whitney test [MWT) P < 0.01), and was greater in
specimens with tubulointerstitial nephritis (TIN) than in those with
glomerulonephritis (ON) (MWT P < 0.001). The expression of EMA(MWT P < 0.01) and type IV collagen (MWT P < 0.05) was greater in
kidney disease than in control specimens. The expression of vimentin
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(MWT P < 0.01), EMA and CD15 (both MWTP < 0.05) was significantly
greater in secondary and than in primary GN. In highly aggressive GN, the
expression of vimentin, EMA (both MWT P < 0.001), CD15 and type IV
collagen (both MWT P < 0.05) was higher than in low grade GN.
Vimentin (Kruskal-Wallis P < 0.05) and EMA expression (Kruskal-WallisP < 0.001) also differed significantly between different types of GN.
Overexpression of EMA and vimentin correlated with clinical (creatinine
and creatinine clearance, hypertension and hemodialysis), histological (%
glomeruli scierosed, crescents, interstitial fibrosis) and immunohistochem-
ical findings (interstitial and glomerular leukocyte subpopulations). Mul-
tiple regression analysis yielded a function that predicted final creatinirte
values (FC) from EMA and type IV collagen: FC —0.718 + 1.333 X
EMA + 0.877 X type IV collagen. Conclusions: (1) Immunohistochemical
studies of markers of renal differentiation (vimentin, EMA and CD15) are
useful in the classifying and determining the prognosis in kidney disease.
(2) Of the markers of tubulointerstitial damage tested here, EMA was the
most reliable indicator of the presence of lesions. (3) EMA and type IV
collagen were the most useful and sensitive markers in distinguishing
between patients with kidney disease and controls. (4) Our method of
quantifying fibrosis is more reliable and reproducible than semiquantita-
tive estimates.
Anti-neutrophil cytoplasmic autoantibodies (ANCA) as systemic vascu-
litis and other autoimmune disease markers. A. Bernat, E. Parra, E. Bea,
I. Ton'egrosa, and A. Perez, Nephrology Service, General Hospital, Valencia,
Spain. We present the results of detection of ANCA in the serum of 170
patients for diagnostic and follow-up purposes. These patients' diseases
were ANCA-related, such as systemic necrotizing vasculitis, idiopathic
rapidly progressive glomerulonephritis (RPGM) type III, SLE, chronic
intestinal inflammatory disease, neutrophilic dermatitis, etc. One hundred
two patients' sera were positive when tested with indirect immunofluores-
cence (hF), 51 of whom, had been histologically confirmed to be an
ANCA-associated disease. In the follow-up of 17 of these patients, 14
showed lower titers of ANCA or they completely disappeared with
treatment or clinical remission. In 3, titers grew higher with clinical
relapse. Out of the 43 patients without histological confirmation (roughly
80% vasculitis, 8% SLE, 12% acute renal failure), the 12 patients who
were followed showed lowered ANCA titers after treatment, or the titers
remained low and steady or disappeared with remission. Nine patients IFI
positive were false positives: 5 corresponded to acute infections (2 in
AIDS patients), 1 vasculitis limited to skin, 1 membranous glomerulone-
phritis, and 2 acute renal failure due to drugs. In all them titers were
lowered or disappeared after treatment. Moreover, 68 patients were
ANCA negative with hF. Twenty-three patients were confirmed in the
follow-up as true negatives, 26 could not be confirmed due to the lack of
follow-up in 15 patients the disease had low activity, was under treatment,
or limited to skin. The remaining 4 patients were confirmed as false
negatives, as they had an ANCA associated disease. The sera of 54
patients were processed by ELISA to find out the antigens to which
ANCA are most frequently directed against: myeloperoxidase (MPO) or
proteinase-3 (PR-3) was found in azurophylic granules of neutrophils. The
results are as follows: 11 patients IIF positive (4 C-ANCA and 7 P-ANCA)
were also positive for MPO. They corresponded to 3 Wegener's disease, 2
RPGM type III, and 6 microscopic panangeitis; 3 patients hF positive (2
C-ANCA, I P-ANCA) were also positive for PR-3 and were all diagnosed
with Wegener's disease; 4 patients were ELISA and hF negative. In the 40
patients hF positive and ELISA negative, we found 16 patients whose
ANCA were directed against antigens different from MPO and PR-3, such
as lactoferrin, elastase, cathepsin G, etc. In 12 patients the disease was
inactive or not ANCA-associated, and in 9 patients we could not confirm
the diagnosis or the activity of the disease. The last 3 could be considered
as false positives. Conclusions: The presence and titer of ANCA in a series
of determinations is a good diagnostic marker, an indicator of the
response to treatment, and a hallmark of relapse in the ANCA-associated
diseases. ELISA is an extremely useful test, not only for confirming the
presence of ANCA, but for to elucidating the antigens to which they are
against and the disease's activity.
Low calcium dialysate stimulates parathormone secretion and its
long-term use worsens secondary hyperparathyroidism. E. Fernández, M
Borras, B. Pais, and J. Montoliu, Nephrology Service, Hospital Arnau de
Vilanova, Lleida, and Department of Medicine and Surgery, University of
Lieida, Lieida, Spain. The long-term clinical effects of the use of low
calcium concentration in the dialysate are largely unknown. For this
reason we studied the influence of low calcium dialysate on parathormone
(PTH) secretion in hemodialysis patients and its long-term effect on the
severity of secondary hyperparathyroidism. In 35 hemodialysis patients we
lowered the dialysate calcium concentration from 1.75 to 1.25 mmol/liter.
Twelve months later serum iPTI-I levels increased significantly from 18.6
to 33.2 pmol/liter, and so did alkaline phosphatase levels from 210 to 330
lU/liter without significant changes in serum calcium or phosphorus levels.
Hemodialysis with low calcium dialysate (1.25 mmol/liter) induced a net
calcium loss in 10 patients, without modifications in ionized serum calcium
levels. In addition, mean serum iPTH increased 20% over baseline levels,
reaching the maximal level at 30 minutes after the start of hemodialysis
with low calcium dialysate. In contrast, mean serum IPTH levels drop
dramatically at 30 minutes of hemodialysis with high calcium dialysate
(1.75 mmol/liter). We conclude that low calcium dialysate worsens sec-
ondary hyperparathyroidism in hemodialysis patients, probably by induc-
ing a negative calcium balance and causing repetitive stimulation of PTH
secretion in each dialysis. The maintenance of normal serum calcium
levels could be due to PTH-induced calcium mobilization from bone.
Tumoral calcifications in hemodialysis (HD) patients. Bone histopa.
thology and follow-up in three cases. M. Saigueira, C. Jarava, J.R. Armas,
A. Lara, J. Vazquez, J. Amor, and A. Palma, Nephrology and Pathology
Services, Hospital Universitario Virgen Macarena, Sevilla, Spain. Periarticu-
lar tumoral calcifications (TC) are multiloculated, calcium-phosphate
deposits that in a few occasions may appear in HD patients. HyperPi, high
Ca X P levels and secondary hyperparathyroidism have been main the
pathogenic factors involved. Recently, TC have been reported in HD
patients with low levels of PTH and low turnover bone disease. Between
1989 and 1992, 3 out of 120 HD patients developed TC greater than 4 cm
in diameter. Patient 1 had massive TC in both shoulders, elbows, hips, and
knees. Patients 2 and 3 developed TC in the right shoulder and patient 1
also had TC in the right elbow. The 3 patients had been taking oral
calcitriol (total dose 300—400 jig). Bicarbonate buffered dialysate con-
tained: Ca 1.75 mmol/liter and Mg 0.5 mmol/liter. Analytical data are:
Patient
Ca
mg/dl
Pi
CaxP
AP
U/liter
iPTH
pg/mi
Al
pg/liter
1 9.7 6.8 67 76 88 53
2 9.6 9.1 86.4 240 800 62
3 10.6 6.9 73 180 1200 43
Undercalcified bone biopsy showed low turnover osteomalacia with 100%
of trabecular surface covered with Al in patient 1 and severe osteitis
fibrosa without Al deposits in patients 2 and 3. Patient 1 died of
cardiovascular complications. Patient 2 had persistent hyperPi. After
subtotal parathyroidectomy, iPTH came to normal levels while serum
levels of Pi remained elevated. After 1 year of follow-up TC size increased.
Patient 3 received i.v. calcitriol, and dialysate calcium was lowered to 2.5
mEq/liter. Pi and PTH levels decreased significantly and TC disappeared
after 6 months. Conclusions: (1) TC can develop with either high or
normal levels of PTH. (2) Hyperphosphatemia is a constant finding. (3)
Extensive TC with normal PTH can be favored by a low bone turnover
related or not related to aluminum.
Efficacy of a single weekly bolus of intravenous calcitriol in severe
secondary hyperparathyroidism. C. Sanchez-Perales, M.J. Garcia-Cortes,
F. Borrego-Utiel, A. Liebana, P. Perez del Barrio, MC. Ruiz Olmo, P.
Serrano, M Rodriguez, and V Perez-Bañasco, Servicio de Nefrologia,
Hospital General de Especialidades, Jaén, and Unidad de Investigacion,
Hospital "Reina Sofia," Córdoba, Spain. The intermittent mode of intra-
venous calcitriol administration has been proven efficacious in lowering
PTH levels. This has been related to higher peak concentration and
greater occupancy of the parathyroid cell vitamin D receptors. However,
the optimal temporal interval of administration has not been worked out.
The aim of the present study was to evaluate two different temporal
spacings of administration of iv. calcitriol in dialysis patients with severe
hyperparathyroidism. Fifteen chronic hemodialysis patients with marked
secondary hyperparathyroidism were randomized into two groups (GI and
GIl). GI consisted of: 8 patients, mean age 49.8 16 years; duration of
dialysis 90.3 43.8 months; intact PTH: 1545.3 480.7 pg/mI; Ca: 10.9 ±
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1.1; P: 5.85 1.2 (mg/dl); FA: 293 86 lU/liter. Gil consisted of: 7
patients, mean age 42.14 20 years; duration of dialysis: 82.85 38.9
months; PTH: 1349.2 343.5 pg/mI; Ca: 10.4 1.08; P: 5.78 1.3
(mg/dl); FA: 343 135 lU/liter (NS). Dialysate calcium was 3 mEq/liter
and CO3Ca was used as the phosphate binder until 3 glday, above
Al(OH)2 was added. Calcitriol i.v. was administered in doses of 3 g at the
end of midweek dialysis to GI and 1 at the end of each dialysis session
to GIl. Calcitriol and phosphate binders were modified for each patient
according to PTH levels and calcium levels were maintained below 11.5
mg/dl and calcium-phosphate product maintained below 70. The dose of
calcitriol ranged from 3 to 9 g per week for each patient. Serum total
calcium, phosphate and alkaline phosphatase were measured weekly and
PTH was measured monthly. Results: (after 12 weeks of i.v. calcitriol
treatment) GI: All patients showed a decrease in serum Concentrations of
PTH (mean 71%). GIl: Two patients showed no decrease in PTH levels.
The other five patients showed a lowering of 56.6% serum PTH concen-
trations. At the end of this period serum total calcium and phosphate
increased and alkaline phosphatase decreased in both groups. However,
final serum calcium was higher in GI and serum phosphate was higher in
Gil. Final changes of each parameter were: GI: PTH: 448 333 pg/mI;
Ca: 12.01 1.4; P: 6.18 1.9 (mg/dl); FA: 239.6 58 lU/liter. Gil (five
responder patients): PTH: 585 404 pg/mI; Ca: 11.7 1.4; P: 8.12 2.4
(mg/dl); FA: 234.4 120.4 lU/liter (NS). In conclusion, a single weekly
dose of intravenous calcitriol administration was highly effective in
suppressing PTH secretion. It could be a useful therapy for the treatment
of severe secondary hyperparathyroidism.
Utility of new biochemical bone markers in the diagnosis and treatment
of secondary hyperparathyroidism. C. Bends, P. Sanz, A. DIaz, E. Gruss, J.
MotellOn, E. Muñoz, IA. Sdnchez-Tomero, V Alvarez, G. Barril, and J.A.
Traver, SeFvicio de NefrologIa, Hospital Princesa, Madrid, Spain. New
biochemical markers for assessing bone formation [the serum c terminal
propeptide (PICP), bone resorption, and serum c terminal telopeptide
(ICTP)1 may have theoretical advantages. We studied 9 hemodialysis
(HD) patients with severe HPT (PTHi > 500 ng/litcr) before and after 2
months treatment with 2 g of iv. calcitriol 3 times weekly. A control group
of 30 normal subjects and a group of 10 HD patients with mild HPT (PTHi
<200 ng/liter) were evaluated. PTHj, ICTP, BAP, AP, BGP, PICP, Ca,
and P were measured in all groups.
Control
HD mild
HPT
I-ID severe
HPT
(Basal)
Severe
HPT
(Treated)
PTHi nglliter 30 114C 535a5 268.1C
ICTP g/liter 2.6 40.3a 52.8'' 47.1
BAP g/liter
AP lU/liter
11.9
166
19.6C
252C
60.4a1
445ab
31.7c
304C
BGPg/liter 2.6 61C 283ah 48C
PICPg/liter 119 179C 261ab 249
a P < 0.05 vs. control; h vs. mild HPT; vs. basal severe HPT.
in the HP group there was a significant correlation of ICTP with AP (r =
0.62), BAP (r = 0.56), BGP (r = 0.50), and PTHj (r = 0.49). In conclusion,
ICTP and PICP are increased in mild and severe HPT, ICTP correlates
with other bone markers, but they have shown no great advantages over
conventional markers either in the diagnosis of HPT, or in the evaluation
of calcitriol treatment.
Total parathyroidectomy (PTX) with autograft. Elective treatment of
severe secondary hyperparathyroidism? M. Goicoechea, JR. Polo, R.
Perez, F. Gómez, MS. Garcia de Vinuesa, F. Anaya, MC. Vozmediano, and
F. Valderrábano, Department of Nephrolo, HGU Gregorio Mararion,
Madrid, Spain. Forty-three patients (17 M, 26 F) on dialysis who under-
went PTX between 1985 and 1994 were studied. The mean age was 44.1
(25—68 years). A follow-up for 2 years was realized after PTX. The main
indications used in assessing the patients for surgery included: a rise in
serum calcium and parathyroid hormone levels (in 23 patients total serum
calcium > 11 mgldl); increased calcium-phosphate product (in 26, serum
phosphorus > 6 mg/dl); radiological evidence of progressive sub-perios-
teal erosions (41); soft tissue calcifleations (17); and symptoms of severe
hyperparathyroidism: bone pain (43) and pruritus (32). Treatment with
calcitriol (oral or intravenous) had to be suspended due to hyperealcemia
and/or metastatic caleifications. Forty patients underwent total PTX with
autograft into forearm; 8—10 slivers of parathyroid gland were implanted
into the supinator muscle of forearm. Three patients were subjected to
total PTX without autograft because less than 4 parathyroid glands were
uncovered. The mean weight of extirpated glands was 6626 933 and
anatomopatologic study showed nodular hyperplasia in 35 patients and
diffuse hyperplasia in 9. No surgical complications appeared, except that in
1 patient there was a recurrent nerve paralysis. Only 1 patient showed
persistent hyperparathyroidism because of the ectopie parathyroid gland
left in the neck. in the rest of the patients there was a highly statistical
improvement in PTH, total calcium, ionized calcium, alkaline phos-
phatase, and reduction in calcium X phosphate product. In all patients but
7, intravenous calcium post-parathyroidectomy was needed. All patients
received oral calcium and calcitriol post-PTX.
Pre
(N = 43)
Month 1
(N = 40)
CaT mg/dl 11.3 0.16 8.1 0.25a
Ca mEq/ 2.7 0.07 1.9 0.06
liter
P mg/dl 6.6 0.25 4.2 0.33a
FA lU/liter 1354 135 1795 219
iPTH pg/mI 963 77 254 78C
Month 6 Month 12
(N = 36) (N = 28)
Month 24
(N = 19)
CaT mg/dl 9.5 0.25a 10 0.2 97 Q3C
Cail mEqi 2.19 0.la 2.3 o.o7 2.3 0.06a
liter
P rng/dl 5.8 0.44 6.4 0.57 6.2 0.7
FA lU/liter 345 65C 313 79 258 28
iPTH pg/mI 290 89C 359 i05 684 302b
C P < 0.01 in relation pre-PTX time (ANOVA); b Seven patients with
recurrence are included
Seven patients (16.2%) had recurrent hyperparathyroidism: 3 during the
first year and 4 after 2 years. In the rest of the patients, symptoms of
hyperparathyroidism and soft tissue ealeifications disappeared. Vascular
ealeifIcations did not change. Total PTX with autograft into the forearm is
a safe and effective procedure for treatment of symptomatic refractory
hyperparathyroidism.
Endothelial factors in patients with end-stage renal failure, secondary
hyperparathyroidism, and vascular calcifications. J. Paydn, M. Alcald, G.
Silgado, R. Perez, P. Gómez, J. Guzmdn, M Ramos, and M. Almaraz,
Departament of Nephrology and Hematology, Hospital S.A.S., Jerez, Spain.
Vascular caleifications are frequent in patients with end-stage renal failure
(ESRF) in hemodialysis. These vascular calcifleations have been related
with secondary hyperparathyroidism. It is known that vascular endothelial
cells are probably the major site of interactions between coagulant and
anticoagulant factors. The anticoagulant properties of the endothelial cells
include their intervention in the protein C (PC)-thrombomodulin system,
the antithrombin III (AT-III)-heparin system and profibrinolitic mecha-
nisms. The aim of this study was to investigate if patients with ESRF in
hemodialysis who present with severe vascular calcifications could suffer
damage on vascular endothelial cells impairing the regulation of factors
synthesized by them and contribute to thrombotic complications in these
patients. Twenty-seven hemodialysis patients were selected and they were
divided into 2 groups. Group I included 10 patients with severe secondary
hyperparathyroidism, with bone radiography showing evidence of ad-
vanced renal osteodystrophy and diffuse calcifications of arteries of several
sizes. Group II included 17 patients with lighter secondary hyperparathy-
roidism, with the bone radiography study showing light signs of renal
osteodystrophy. A control group consisting of 20 normal volunteers was
included for comparison. Blood samples were obtained for AT-Ill, free
protein S (PS), PC and von Willebrand factor (vWF).
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Control
Group I Group II Group
AGE years 46.4—10.9 41—9.2 40—10
D.HD months 97.8—23.9 36.2—25.6 —
iPTH pg/mI 957—371 121—96 —
Activ PC % 100—22 113—26 110—29
Free PS % 71—24 97—17 105—25
AT-Ill % 92.4—17.4 96—22.9 93.8—10
vWF % 87—65.8 105—61 88—12
The mean levels of free PS were significantly lower in patients of group I
than those found in group II. The mean 1PTH was significantly higher in
group I compared to patients in group II, and also the mean duration in
hemodialysis (D.HD) in group I was significantly higher than in group II.
No differences were observed in means of age, PCA, AT-Ill and vWF
between groups I and II. In conclusion, our study reported an important
free PS deficiency in patients with ESRF and diffuse vascular calcifications
that could suggest defective synthesis of PS by endothelial cells due to
impaired regulation of its functions secondary to the vascular calcifica-
tions. The free PS deficiency of these patients can increase the risk of
thrombotic complications.
Role of endogenous calcitonin (CT) on secondary hyperparathyroidism
(2°HPT) in chronic renal failure (CRF). S. Ta/ion, A. MartIn-Maio, I.
Berdud, Y Aimadén, M. Rodriguez, and P. Aijama, Hospital Universitario
Reina Sofia, COrdoba, Spain. In CRF, CT is increased despite hypocalce-
mia. The aim of this study was to evaluate whether the presence of CT
modifies the 2°HPT in CRF. Uremic rats (5/6 Nx) were divided into 2
groups: (1) thyroparathyroidectomy with parathyroid autotransplant
(CT—); and (2) thyroid intact with parathyroid autotranspiant (CT+).
Thyroxine (2 jsg/thrice weekly) was administrated to CT— rats. All rats
received either a normal 0.6% (NPD) or a high 1.2% (HPD) phosphorus
(P) diet. After 7 days, the results were:
CT- CT+
NPD HPD NPD HPD
(N =8) (N = 12) (N =8) (N =9)
Ca 9.1 0.3a 6.9 02b 9 0.2" 6 0.3
P 6.3 0.4 8.6 0.5 6.6 06b 9.5 0.6
Cr 0.85 0.03 0.92 0.05 0.93 0.1 1 0.04
iPTH 47 3.7 73 12 60 6.7 69 18
ap < 0.001 vs. CT— HPD; bp < 0.001 vs. CT+ HPD
iPTH levels were not significantly different in CT+ versus CT— on the
same diet. Calcium significantly decreased in CT+ rats on HPD. Our
results suggest that the absence of CT does not modify 2°HPT in CRF.
Serum calcium can modify set-point in uremic patients in hemodialysis.
J. Borrego, M Rodriguez, Y. Almadén, I. Berdud, A. Cardoso, A. Martin-
Malo, and P. Aijama, Hospital Universitario Reina Sofia, Córdoba, Spain.
The set-point is increased in uremic severe secondary hyperparathyroid-
ism. Calcitriol modifies set-point and can increase the serum calcium. At
present there is a tendency to lower the dialysate calcium concentration,
voiding the calcemic action of calcitriol. Is not clear if the serum calcium
change can have influence on set-point, independently of calcitriol action.
Aim: To determine if serum calcium changes can modify set-point.
Material and methods: The study consisted of 7 uremic patients on
hemodialysis, with mild secondary hyperparathyroidism. We studied the
PTH-calcium curve after 2 weeks of hemodialysis with dialysate calcium
concentration of 2.5 mEq/liter (for decreasing the serum calcium) and
after 2 weeks with dialysate calcium concentration of 3.5 mEq/liter (for
increasing serum calcium). Results: After 2 weeks of dialysis with a
dialysate calcium concentration of 2.5 mEq/liter and a change in dialysate
calcium concentration of 3.5 mEq/liter, set-point changed. There was a
positive correlation between set-point increase and serum calcium in-
crease (r = 0.71, P < 0.01).
dCa
Basal
iPTH iPTH max
Basal
calcium Set-point
2.5 420 107 940 258 1.18 0.07 1.11 0.04
3.5 363 109 816 188 1.25 0.04 1.16 0.03
Conclusion: The changes in serum calcium induced parallel changes in
set-point.
Calcitriol in uremic secondary hyperparathyroidism modifies the Ff11-
calcium relation: The role of serum calcium. J. Borrego, A. Romero, Y.
Almadén, I. Berdud, A. Martin-Malo, M. Rodriguez, and P. Aijama, Hospital
Universitario Reina Sofia, COrdoba, Spain. Calcitriol (CTR) decreases PTH
in uremic patients. Moreover, the CTR decreases the set-point; however,
this occurs in patients without increase in serum calcium after the CTR
administration. CTR treatment increases serum calcium levels in the
majority of patients. Aim: To analyze if the calcitriol effect in set-point can
change according to serum calcium levels. Material and methods: We
studied 7 uremic patients on hemodialysis, with mild secondary hyperpara-
thyroidism, before and after CTR treatment. PTH-calcium curve deter-
mination: A hemodialysis session with dialysate serum calcium 0.63
mmol/liter (for PTH stimulation) and another dialysis session with dialy-
sate serum calcium 1.75 mmol/liter (for PTH inhibition). Results: After
CTR treatment the PTH-calcium curve is displaced to the right, with a
significant correlation between the increase in serum calcium and the
increase in set-point (P < 0.001 and r = 0.88).
CTR iPTH Basal calcium Set-point
PRE 616 127 1.07 0.05 1.05 0.02
POS 401 168 1.19 0.03 1.13 0.03
a < 0.05
Conclusions: CTR treatment increases set-point even in the patients with
decreased PTH levels. The changes in set-point have a correlation with
serum calcium increase.
Is the reduction of calcium concentration in dialysis useful in patients
treated with high doses of Vitamin D3? X Cuevas, M Chine, M. Fuiquet,
M. Ramirez Areliano, R. Cano, P. Ruiz, M. Buxeda, and E. Canadell,
Nefrologia I Laboratorio, Hospital Terrassa, Barcelona, Spain. The calcium
concentration ([Ca]) in hemodialysis (HD) is normally 3.5 mEq/liter. It
must be reduced in patients treated with high doses of Vitamin D3 to avoid
the severe complications which could be derived from treatment. Objec-
tive: To know the calcium balance according to the calcium concentration
in patients with and without high doses of 1,25(OH)2D3 by iv. and orally.
Materials and methods: In a 3 hour HD session, we took blood samples
at the start, 0.5 hour, 1.5 hours, and at the end of the session and 1 hour
and 2 hours post-HD, in order to: (1) measure calcemia in patients not
treated with 1,25(OH)2D3; (20 HD sessions in 5 patients with [Ca1 =
3.5 mEq/liter; 24 HD sessions in 6 patients with [Cat I = 2.5 mEq/liter;
3 HD sessions in 3 patients with [Ca ] = 3mEq/liter). (2) measure iPTH
in patients not treated with 1,25(OH)2D3; (2 HD sessions in 2 patients
with [CaI = 3.5 mEq/liter; 3 HD sessions in 3 patients with [CaI =
2.5 mEq/liter; 3 HD sessions in 3 patients with [Ca1 = 3 mEq/liter).(3) measure Calcemias and iPTH with [CaI = 2.5 mEq/liter;(2 HD sessions in 2 patients with 1,25(OH)2D3 oral doses = 2 jig/post-
HD; 1 HD session in 1 patient with 1,25(OH)2D3 i.v. at doses =
1 jsg/post-HD; 1 HD session in 1 patient intoxicated by 1,25(OH)2D3).
Results: The [CaI = 3.5 and 3 mEq/liter causes a positive calcium
balance that persists 2 hours post-HD with respect to the initial levels of
calcium. iPTH drops as a result of the positive calcium. The [Ca1 = 2.5
mEq/liter neither changes the calcemia during hemodialysis nor by 2 hours
post-HD. The iPTH increases during HD and stays high by 2 hours
post-HD as a consequence of the negative calcium balance. Conclusion:
The [Ca] = 2.5 mEq/liter in dialysis concentration causes a negative
balance, even in patients treated with high doses of 1,25(OH)2D1.
Are high doses of 1,25(OH)2D3 the alternative to surgical parathyroid-
ectomy (PTHx) in patients with refractory secondary hyperparathyroid-
ism (HPTs)? X Cuevas, M. Chine, M Fuiquet, M. Ramirez Areliano, R.
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Cano, P. Ruiz, At Buxeda, N. Barba, and L.L. Veciana, Nefrologia
Laboratorio, Hospitals Terrassa and Cetirsa, Barcelona, Spain. The treat-
ment for HPTs is traditionally surgical but, recently it has published that
"pulses" of 1,25(OH)2D3 could be another form of treatment, known as
"chemical" PTI-h. Objective: The description of the evolution and the
complications of the treatment with pulses of 1,25(OH)2D3 in patients on
hemodialysis (HD). Materials and methods: Fifteen patients: aged 50.4
18.8 (20—83 years); sex = 6M/9F; time on HD = 54.8 41.4 (10—165
months). All those patients treated by conventional Vit D3 were included
in this medical protocol and who had iPTH = 921 354 (475—1672). Four
out 15 patients were exitus within 1—5 months after they started the
treatment. The remaining 11 patients were divided into two groups: (A)
Treatment proved unsuccessful, they will need PTHx. (B) Treatment
proved successful. We analyzed and compared in both groups for: age,
time on HD, time of treatment with Vit D3, biochemical results (Ca, P,
A.P., iPTH, Al, CaxP, and average doses of Vit D3). We performed such
analyses every 3 months. All the patients were dialyzed with a calcium
concentrate 2.5 mEq/liter. Severe complications during the treatment are
described.
Group A (PTHx) Group B
N of patients 6 5
Age, years 51.3 24.7 (20—83) 43.8 10 (28—56)
Time HD, months 36.8 22.4 (10—64) 45.4 27 (11—78)
Time following, 11 2.3 (8—13) 8.2 2.5 (5—11)
months
iPTI-1 (start) 1148 251 (790—1572) 658 174 (473—912)
3 months iPTH 741 295 (385—1257) 521 336 (217—1073)
VitD3 (post-HD) 2.11 1.05 (0.7—4) 1.4 0.54 (1—2)
6 months iPTH 426 118 (245—564) 401 148 (212—589)
VitD3 (post-HD) 2.34 1.23 (0.7—4) 1.54 1.16 (2—3)
9 months iPTH 479 130 (326—637) 264 9 (255—274)
VitD3 (post-HD) 1.64 0.56 (0.7—2) 0.8 1.03 (0.2—2)
Only 3 patients in group A have been affected with severe complications:
1 patient had a hypercalcemic encephalopathy; 1 patient had a calciphi-
laxia; and 2 patients showed extensive vascular calcifications. Conclusion:
The treatment of HPTs with high doses of VitD3 is not a universal
alternative to surgical PTHx; furthermore, it could be the cause of severe
complications if the treatment is maintained for a long time in "no
responder" patients.
Recurrence after total parathyroidectomy (PTX) with autograft. PTH
gradient as assessment of parathyroid graft function. M. Goicoechea, R.
Perez, JR. Polo, F Gomez, £ Garcia de Vinuesa, F. Anaya, E. Verde, At
Lago, and F Valderrábano, Department of Nephrology, Hospital General
Universitario Gregorio Maranon, Madrid, Spain. The aim of the study was
to evaluate the recurrence rate after total PTX with autograft and PTH
gradient as assessment of parathyroid graft function. Thirty-seven patients(16 males, 21 females) who had PTX and were on dialysis were studied.
The mean age was 45.9 (25 to 68 years). The patients were subjected to
PTX with autograft into the forearm between 1985 and 1993. The mean
time on dialysis was 83 46 months (mean so). We defined recurrence
of hyperparathyroidism as patients who presented PTH values increased
after they have reached a normal range after PTX. These patients also had
symptoms of hyperparathyroidism and/or hypercalcemia and/or hyper-
phosphatemia. PTH gradient (relation between PTH values on samples
from both forearms) was measured to evaluate the function of parathyroid
tissue autografted into forearm. In all patients but 1 (persistent hyper-
parathyroidism), PTH levels decreased after PTX. Recurrence appeared
in 7 patients (18.9%; 3 during the first year and 4 after 2 years). Only 4 of
the 7 patients had hypercalcemia, 4 hyperphosphatemia, and 2 of them
had important bone pain and 3 pruritus. No significant differences were
found in total calcium, ionic calcium, phosphorus, alkaline phosphatase
values post-PTX and phosphorus binders and calcitriol doses received,
between the group of patients with recurrence and rest of the patients. In
5 out of 7 patients with recurrence PTH gradient was measured (1 died
and another received a kidney allograft). PTH gradient was > 5 in the 5
patients with recurrence, while PTH gradient was <5 in all patients
without recurrence. Autograft was extirpated in these patients, and PTH
gradient decreased in all but 1.
n°1 n°2 n°3 n°4 n°5
PTH 1028/205 2116/300 4539/650 1500/159 428/87
Gpre (5) (7) (7) (10) (5)
PTH 226/215 337/29.8 534/324 50.8/38 99/93
Gpos (1) (11) (1.6) (1.3) (1)
in conclusion, after PTX with autograft, 19% of the patients had
recurrence. PTH gradient assay is a useful and easy test to determine the
autograft function and diagnose recurrence of hyperparathyroidism.
Control of hyperparathyroidism with low calcium bath in patients not
treated with calcitriol. IL. Terue4 A. Aguilera, I Navarro, R. Marcen, F.
Liano, and I Ortuno, Hospital Ramon y Cajal, Departamento de Nefrologia,
Madrid, Spain. A diminution of the concentration of calcium in the dialysis
bath to 5 mg/dl has been shown to be useful and safe in patients treated
with calcitriol. The use of this concentration of calcium in patients not
receiving vitamin D supplements is disputed, due to the possibility that the
oral supplements of calcium are not sufficient to avoid a negative balance
of calcium and an unimprovement of the secondary hyperparathyroidism.
To elucidate this aspect, we carried out a prospective study in 24 patients
who were dialyzed with a concentration of calcium in a bath of 6.5 mg/dl
and were not treated with vitamin D in the previous 2 years. Those
patients were dialyzed for 1 year with a concentration of 5 mg/dl calcium
in the bath. The dose of calcium carbonate was adjusted to maintain a
calcemia between 8 and 10 mg/dl, and aluminum hydroxide was adminis-
tered if phosphotemia was superior to 6 mg/dl. After 1 year of dialysis with
a calcium concentration of 5 mg/dl in the bath, the dose of oral calcium
carbonate was increased from 3.2 2.5 up to 8.1 4.7 g/day (P C 0.001).
Seventeen patients (71%) could do without the aluminum hydroxide and
in the 7 remaining cases the doses could be reduced from 1,120 575 to
840 399 mg/day (P < 0.05). The amount of aluminum in the blond
diminished from 37 28 to 26 24 (P < 0.05). In the whole group, we
did not find a variation in the intact PTH levels (basal: 308 117; 1 year
301 238 pg/ml) or of alkaline phosphatase (204 82 years 208 111).
PTH levels diminished in 54% of the patients, remained stable in 25%,
and increased only in 5 patients (3 of them did not take an adequate
supplement of calcium, and the other 2 started treatment with oral
calcium). Conclusions: The use of a calcium concentration of 5 mg/dl in
the bath is safe in the majority of patients not treated with ealeitriol. In
79% of the patients the oral supplements of calcium carbonate is sufficient
to control the secondary hyperparathyroidism. Isolated cases could need
vitamin D supplements.
IGF-1 in predialysis patients. R. Montes-Delgado, MA. Guerrero Riscos,
C. Martin Herrera, PP. Garcia-Luna, F Garcia de Pesquera, J.L. Pereira,
and J. Mateos Aguilar, Nephrology Service, Clinical Nutrition Unit and
Nuclear Medicine Service, University Hospital Vitgen del Rocio, Seville,
Spain. It has been proposed that insulin-like growth factor-i (IGF-1) is a
marker of nutritional status in hemodialysis patients, and in relation with
triceps skinfold thickness (TST), is considered as one estimation of fat
compartment. The aim of our study was to investigate the correlations
between blood IGF-i and different nutritional parameters in a group of 37
predialysis patients with ereatinine clearance lower than 25 ml/min/i.73
m2. IGF-i was determined by RIA (Nichols Institute). The quantity of
protein ingested/kg/day was calculated on the basis of urea nitrogen
appearance rate, by the Maroni procedure. The rest of the measurements
were performed by laboratory standard methods. TST was quantified by a
Lange caliper. The mean standard deviation of blood IGF-1 was 214
110 ng/ml (range: 82.6—573.6 ng/ml). We did not find a significant
statistical correlation between IGF-i and the other anthropometric mea-
sures, included TST, with the exception of body mass index (BMI). On the
contrary, there were significant statistical correlations with the following
parameters: age (r = —0.44; P < 0.01), hemoglobin (r = 0.34; P < 0.05),
BMI (r =
—0.33; P C 0.05), lymphocytes/mm3 (r = 0.38; P C 0.05),
albumin (r = 0.33; P C 0.05), prealbumin (r = 0.39; P C 0.05), retiool
binding protein (r = —0.66;P C 0.005), and protein ingested/kg/day (r =
0.59; P C 0.0005). In conclusion, blood IGF-1 values are similar to the
normal population, but with greater dispersion. In our experience, IGF-i
is a marker of visceral protein compartment and the protein ingested, but
not of the fat compartment. Young patients have greater values of IGF-1.
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There exists a very significant negative correlation between retinol binding
protein and IGF-1.
Erythropoietin (EPO) in patients with ferropenia and high ferritin
levels. C. Sanz-Moreno, J. Naranjo, E. Jimenez Vega, D. Sanz-Guajardo,
f.M. Garrancho, and J. Botella, Hospital Puerta de Hierro, Madrid, Spain.
The patients with low serum ferrum (Fe) show a resistance to treatment
with EPO, which can be corrected after Fe administration, usually
intravenously (i.v.). There is a special problem in the cases with very high
values of ferritin and simultaneously low Fe. Since desferroxiamine (DFO)
is an excellent chelant of Fe, we have decided to use it in these cases in
order to improve the hemosiderosis and to get a better response to the
EPO. We have studied 12 patients with low serum Fe (46.2 13.8 .rg/dl)
and high ferritin levels (940 281 ng/ml), treated with EPO (7500 4800
U/i.v./week) with a poor response (Hct 24.6 1.3%); after Fe i.v.
administration (120 mg/week) the response to the EPO was better (Hct
30.7 3.3%), but with an increase in the ferritin (1041 250 ng/ml).
Therefore, we stopped the Fe administration and began the DFO
administration (500 mg/i.v./post-HD). The ferritin values were lowered to
751 307 ng/ml after one month DFO treatment and to 654 289 after
2 months; the Fe increased to 55.2 28.6 j.rg/dl; the Hct and hemoglobin
were stable in 30% and 10.5 g/dl, and the number of reticulocytes was also
stable. We tried to maintain the Epo doses unchanged in order not to
interfere with DFO effects, but in 2 patients we needed to lower it, due to
a Hct of 40%. We concluded that DFO treatment is useful in ferropenic
patients with high ferritin levels, since it keeps the EPO response without
Fe administration and it improves their hemosiderosis simultaneously.
Possibly, treatment has to be prolonged in order to obtain a better
depletion of Fe deposits.
Patients in predialysis and prevalence of HCV. Multicentric study in 18
Spanish Hospitals. Coordinators: G. Barril and IA. Traver, Servicio de
NefrologIa, Hospital de Ia Princesa, Madrid, Spain. We have considered
predialysis patients to be those with a creatinine clearance below 20
mi/mm. We extended the preliminary study to 318 patients in 18 hospitals
in Spain. We found 20 patients with HCV+ antibodies, which represents
a global prevalence of 8.2%, clearly above that of the healthy Spanish
population. The dispersion according to the centers is very great, with the
prevalence fluctuating between 0—4%. We have considered age, sex, time
of evolution of disease, surgical antecedents, renal and/or hepatic biopsy,
catheterisms, transfusions, and hepatopathy (acute hepatitis, presence of
HBcore, etc.). The average age is 57.7 15.7 years, with 64 males and 36
females. We found a significant difference between the HCV+ and
HCV— groups of patients in relation to the transfusional antecedents P <
0.001. The significance rose with a number of these (P < 0.001) and the
surgical antecedents + hepatic and renal biopsies + catheterisms. It
should be pointed out that 75% of the patients with antecedents of acute
hepatitis are HCV+; there were no statistically significant differences
between the rest of the parameters analyzed. Conclusions: (1) There is a
high prevalence of HCV antibodies in predialysis patients in the sample
analyzed. (2) The antecedents of surgery + catheterisms and biopsies
increased the risk of infection by c virus, as well as transfusions. (3) Studies
are necessary to determine the factors, in addition to transfusions, that
make infection by HCV possible.
Effect of recombinant erythropoietin (EPO) on the progenitor cells
(PC) in patients with chronic renal failure. A. Perez, H. Sancez, A. Lopez,
M Linares, A. Miguel I. Torregrosa, R. Molt, and F. Carbonell, Department
of Nefrologia-Hematologia, Hospital General, Valencia, Spain. We studied
the concentration of erythroid PC (BFU-E) and myeloid PC (CFU-GM)
cells in peripheral blood and bone marrow, and the percentage of these
cells synthesizing DNA in 18 anemic patients with chronic renal failure,
before and 8 and 20 weeks after they started treatment with EPO. We also
studied the production of stimulator substances of erythroid growth
(BPA) by the mononuclear cells (MNC) when challenged with fitohem-
agglutinin. The concentration of BFU-E in peripheral blood was 194
137, 202 134, and 129 58 per 5.10 MNC at the points considered in
the study, with 40, 52 and 43% in DNA synthesis, respectively. The
concentration of myeloid colonies was 74 46, 119 86, 93 55 per 5.10
MNC with 42, 37, and 34% in synthesis at the different points in time. In
bone marrow the concentration of BFU-E was 126 81 and 100 56 and
CFU-GM was 56 32 and 60 34 per 2.10 MNC before and after 20
weeks with EPO. We examined the effect of EPO on the PC and the
influence of the treatment with chronic hemodialysis, the levels of
hemoglobin achieved, dose of EPO and white blood cells and platelet
levels. The results of the BPA show a lack of production of hematopoiesis
stimulating substances in these uremic patients, independent of the use of
EPO.
Advanced diabetic nephropathy without prior adequate control. A.
Araque, C. Alamo, M. Praga, C. Mon, E. Herndndez, T Ortuno, and IL.
Rodicio, Hospital 12 de Octubre, Madrid, Spain. Diabetic nephropathy is
the most common etiology of end-stage renal failure in many developed
countries. Strict metabolic control and ACE inhibitors can halt the
progression to renal failure when started early in the course of the disease.
We have studied 74 diabetic patients (age 61 11 years) who were
admitted to our hospital from 1984—1993. Fourteen (18%) were diabetes
mellitus (DM) type I and 60 (8 1%) type II. Serum creatinine (Sr) at
admission was 4.2 2.7 mg/dl and proteinuria 3.5 2.6 g/24 hours.
Forty-three patients (58%) had not been regularly controlled before
admission. Regular control was more frequent in DM-I (65%) than in
DM-II (36%). Only 14 cases (18%) were taking ACEI at admission. The
most common reasons for admission were detection of renal insufficiency
or nephrotic syndrome (65%) and cardiac failure (25%). Patients were
divided according to the date of admission: 1984—1988 (Group I, 39 cases)
and 1989—1993 (Group II, 35 cases). There were no differences between
both groups regarding age, percentages of DM-I or DM-II, cases with
prior adequate control, arterial hypertension, or ischemic cardiopathy. Sr
was lower in the second period (Group I: 5.1 2.9; Group II: 3.4 2.1
mg/dl; P < 0.01), but proteinuria was similar (3.3 2.1 vs. 3.7 2.9 g/day).
The percentage of patients taking ACEi increased from 7.6% (Group I) to
31.4% (Group II) (P < 0.05). Most of the patients showed a rapid
worsening of renal function; after one year of follow-up, Scr had increased
53%, and one year later, 72% with respect to initial values. In conclusion,
an important proportion of diabetic patients reaches advanced renal
insufficiency without an adequate previous medical control. Most of the
patients have DM-II and their progression to end-stage renal failure is
very rapid. Although the initial Sr is lower and the number of patients
taking ACEi has increased in the last years, specific programs to detect
and control these diabetic patients in the earlier phases of the disease are
urgently needed.
Treatment of the hypercholesterolemia with LDL-apheresis and its
repercussion on atheromatous plaque. F. Anaya, MI. Seoane, T Perez
Maestro, F. Gomez Candera, A. Tejedor, MS. Garcia de Vinuesa, R. Perez
Garcia, M. Goicoechea, and F. Valderrabano, Servicio de Nefrologia,
Hospital General Universitario Gregorio Maraflon, Madrid, Spain. Athero-
sclerosis (AT) with its clinical manifestations of coronary heart disease,
cerebrovascular insufficiency and peripheral artery disease is always the
most frequent cause of morbidity and mortality. Recently it has been
shown that reduction of LDL-choiesterol is followed by a decrease of
ischemic heart disease incidence, bridling and even regressing the athe-
romatous plaque (AP). Double filtration plasmapheresis (DFPP) is a
therapeutic procedure that selectively removes the atherogenic lipopro-
teins from plasma. After a plasma separation (PS) plasma was passed
through a second filter in which macromolecules were selectively removed
and discarded. The duration of the process is 2—3 hours. The filtration
volume for the first filtration was 3.6 to 5.0% of the body weight and 5 to
10% of separated plasma in DFPP (200 —300 ml). Fluid was regulated with
5% albumin solution. The replacement volume was about 1/6 of filtration
volume in DFPP. We report our experience with a program of LDL-
apheresis for a duration of 2 years. The 11 patients treated included: 6
heterozygous familial hypercholesterolemia (HEFH), 1 homozygous FH(HOFH), 3 familial combined hyperlipidemia (FCHL), and 1 primary
sclerosing cholangitis (PSLCO). Criteria for their inclusion were hyper-
cholesterolemia during a minimum period of 6 months, in spite of diet and
drugs combined therapy. All patients had X-ray documented coronary
atherosclerosis and peripheral signs or symptoms of hyperlipemia. Labo-
ratory examinations of blood and filtered fluids were done immediately
before and after each treatment: triglyceride (TG), total cholesterol (TC),
low density lipoprotein cholesterol (LDL), high density lipoprotein
(HDL), apolipoprotein A (ApoA), apolipoprotein B (ApoB), and lipopro-
tein a [Lp(a)I were determined, and treatment frequency was once or
twice per month. Vascular access was arteriovenous fistula (AVF).
Results: LDL apheresis treatment induced TG, TC, LDL, ApoB and
Lp(a) mean levels; there was a significant (P < 0.001) decrease to 1/3 of
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the initial values in each session. Rebound was observed during the
follow-up. All patients showed improvement of some striking features,
such as resolution of cutaneous and tendinous xanthomas after 4—6
months of the beginning of the program, reduction of the severity of
angina pectoris, and improvement of exercise capacity. Prevention of
progression or regression of coronary atherosclerosis remains to be
stressed. We conclude that LDL apheresis is an efficient procedure to
lower serum cholesterol in patients who do not respond to diet-pharma-
cological treatment of hypercholesterolemia.
Usefulness of clinical evaluation in the diagnosis of vascular access
malfunction in chronic hemodialysis (HD) patients. E. Hernández, A.
Araque, M. Praga, C. Alamo, J. Abad, J.M. Alcázar, f.M. Morales, and J.L.
Rodicio, Hospital "12 de Octubre", Madrid, Spain. The maintenance of an
adequate vascular access (VA) for HD is a major problem in HD patients,
and it represents one of the most common reasons for admission in these
patients. Our aim was to evaluate prospectively the sensitivity (SE) and the
specificity (SPE) of clinical and analytical data in the diagnosis of VA
malfunction in our HD population (80 patients, aged 53 15 years). From
October 1992 to May 1994, 30 fistulograms (F) of VA were performed on
patients with some of following conditions: poor blood flow (PBF) (<300
mI/mm); high venous pressure (HVP) when blood flow is 300 mI/mm,
(>150 mm Hg when autogenous VA or >200 mm Hg when PTFE grafts);
recirculation (R) >15%. Proximal stenosis (arterio-venous anastomosis or
proximal vein) was found in 8 cases (26%) and distal stenosis in 15 (50%)
(graft-vein anastomosis 8, subclavian or cephalic veins 7). Two F were
normal and 5 only demonstrated aneurysmal disease without stenosis. The
SE and SPE were:
Proximal stenosis DistaI stenosis
PBF <300 R> 15% HVP R> 15%
SE 50% 100% 86% 66%
SPE 100% 61% 53% 46%
In conclusion, VA malfunction due to proximal stenosis can be readily
suspected upon clinical evaluation. When distal lesions are involved, the
diagnosis based on clinical evaluation is less accurate.
Sixteen years experience of renal replacement therapy (RRT) in
diabetic patients. C. Dali Anese, R. Perez-Garcia, F. Gomez Campdera,
MS. Garcia Vinuesa, M. Goicoechea, and F. Valderrabano, Department of
Nephrology, Hospital General "Gregorio Marañon," Madrid, Spain. To
evaluate diabetic patients on RRT outcome we studied all end-stage renal
failure diabetic patients treated in our hospital from 1978 to 1993. There
were 104 patients (59 males and 45 females), and 87 were type I and 17
type II diabetics. Their mean age at beginning of RRT was 52 13 years(±sD). Hemodialysis (HD) was the first modality of treatment for 70
(67%) diabetics and CAPD for 34. Forty-eight out of 70 patients on HD
were dialyzed in the hospital unit, 18 in the satellite units, and 4 at home,
which means a higher proportion of diabetics on CAPD and on HD were
in the hospital unit. Diabetics allocated to CAPD were 12 years (as a
mean) younger than patients allocated to HD (P < 0.01). During the
follow-up period (45 40 months) 48 patients changed their treatment
modality and 30 patients received a kidney allograft. Relative risk of
drop-out was higher in CAPD compared to HD. Clinical complications,
ocular and cardiovascular, were observed in more than 80% of the
patients. By the end of 1993, 42 patients were dead. Infections (24%) and
cardiovascular diseases (19%) were the 2 most frequent causes of death.
Unknown origin deaths represent 28% of all deaths. The overall survival
was 90%, 83%, 73%, 60%, and 52% at 1, 2, 3, 4 and 5 years, respectively,
without any significant differences between patients on CAPD and pa-
tients on HD, in spite of the significant difference in age between both
groups. Data analysis by logistic regression showed that younger age and
kidney transplantation had a positive independent effect on survival.
These results suggest that HD may be superior to CAPD in diabetic
patients. Kidney transplantation would be the first choice RRT in diabetic
patients.
Infection by hepatitis C virus (HCV) reduces the response to the
hepatitis B vaccination. J.F. Navarro, fL. Teruel, R. Marcen, M. Mateos, F.
Liano, A. Aguilera, and J. Ortuflo, Departamento de Nefrologia, Hospital
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Ramón y Caja4 Madrid, Spain. Infection by hepatitis B virus (HB)
continues to be a risk for patients on I-ID. The seroconversion after the
vaccination is estimated to occur when the antibody titer (HB5-Ac) is
higher than 10 lU/liter. Recently, however, a titer higher than 100 lU/liter
has been considered necessary to guarantee an effective protection. We
studied prospectively the evolution of HBs-Ac in 56 seronegative patients
on HD after the primary vaccination against HB (3 doses, Engerix B, 40
jig). In 43 cases (76%) seroconversion (HBs-Ac 100 lU/liter) was ob-
served, but a protective response (HBs-Ac > 100 lU/liter) was only
produced in 30 (56%). After 1 year, of these 30 cases, only 1(3%) had lost
his HBs-Ac; meanwhile, 12 of the 13 patients (92%) with an inadequate
response (HBs-Ac between 10 and 100 lU/liter) did not have detectable
antibodies (P > 0.01). No differences existed regarding age, sex, time on
HD, albumin, Pc,, nor Kt/V. Nevertheless, infection by HCV does
influence the immune response. Twenty-seven of the 43 cases without
infection by HCV (63%) achieved an effective immunity, but only 3 of 13
HCV+ patients (23%) reached a HB5-Ac titer higher than 100 lU/liter
(P > 0.01). Conclusion: After a vaccination against HB, one should
consider that an effective protection exists only when the HBs-Ac titer is
higher than 100 lU/liter. Infection by HCV can reduce the effectiveness of
this vaccination.
Present indications of adrenogens for uremic anemia. The erythropoi-
etin era. A. Aguilera, fL. Tenwl, G. Garcia, R. Marcen, J. Navarro, F.
Liaflo, and J. Ortuno, Hospital Ramon y Cajal, Departamento de Nefrologia,
Madrid, Spain. The high cost of human recombinant erythropoietin
(rHuEPO) and its secondary effects have induced us to reconsider the
treatment of chronic renal insufficiency anemia with adrenogens. We
reviewed our experience during the last 15 years with the proposal to
identify the indications, response conditioning, and secondary effects.
Eighty-four patients (67 males and 17 females) received decanoato of
nandrolona (DN), 200 mg/week i.m., in repeated cycles of 6 months, with
a total of 142 cycles. The hemoglobin (I-Tb) increased from 6.9 to 8.7 mg/dl
at the end of the first cycle (P < 0.01, ANOVA); this increment had no
relation to the sex, basal Hb nephropathy, or the doses of DN corrected
for weight. However, we observed a relation with the age: the mean
increase of Hb was 0.8 g/dl under 46 years (N = 28), 1.8 between 46 and
55 years (N = 28), and 2.7 over 55 years of age (N = 27) (P < 0.01 between
the groups). In the latter group the Hb at the end of treatment was 10.1
+ 1.6 g/dl. Those levels of Hb were maintained for 1 year in 55% of the
cases. From the second month of treatment an increment in triglycerides
(159 to 199 mg/dl) and dry weight (mean of 1.74 kg) was seen. Both
parameters stabilized and later returned to basal values 5 months after the
suspension of treatment with DN. There were no important modifications
in the arterial pressure or in the hepatic enzymes. In 10 autopsy cases we
did not find hepatitis hepatomas or cancer of the prostate. The specific
prostatic antigen measured in 19 patients did not undergo modifications
either during or post-cycle. Hirsutism was observed in many women.
Conclusions: DN is a valid therapeutic option for males older than 55
years of age with uremic anemia in whom we obtain a similar response to
rHuEPO. DN is less expensive, more prolonged, and has fewer relevant
secondary effects.
Lipoprotein(a) levels and vascular access (VA) survival on chronic
hemodialysis. E. Herndndez, A. Araque, C. Alamo, R. Sanchez, M Praga,
f.M. Alcázar, L.M Ruilope, and J.L. Rodicio, Hospital "12 de Octubre,"
Madrid, Spain. Lipoprotein(a) (Lpa) is an independent risk factor for
cardiovascular complications in the general population and in hemodial-
ysis (HD) patients. Increased Lp(a) levels have been reported as a possible
predictor of vascular access (VA) occlusion in HD patients. We have
prospectively studied, from April 1993 to April 1994, the relationship
between VA survival and Lp(a) levels in 40 HD patients. Lp(a) levels were
measured by ELISA in all patients in April 1993. Statistical analysis was
performed with the Mann-Whitney test to unpaired data and cumulative
survival of VA was calculated by the Kaplan-Meier method; failure of VA
was considered when it presented complications that required surgical
repair or transluminal angioplasty. Thirteen patients showed failure of VA
and the cumulative survival of VA after 1 year of follow-up was 66%.
Lp(a) levels were higher in patients with failure of VA (33 31 mg/dl vs.
23 26 mg/dl), but this difference did not reach statistical significance.
The VA survival in patients with Lp(a) higher than the mean value plus
one standard deviation (53 mg/dl) was lower than in the remaining (52%
vs. 70%, P = 0.11), and this difference attained significant value when we
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analyzed the patients with Lp(a) values higher than mean value plus two
standard deviation (79 mgldl); (25% vs. 71%; P = 0.0013). Our results
suggest that patients with the highest levels of Lp(a) are at risk of
developing complications in their VA and they show lower VA survival.
Effects of low intravenous dose of L-carnitine in patients on hemodi-
aysis. B. De Los Reyes, and R. Perez Garcia, Spanish Collaborative Study of
L-Carnitine on Hemodialysis. L-carnitine is a key factor in mitochondrial
oxidation of long-chain fatty acids. It also regulates the acyl CoA/CoASH
ratio within mitochondria. Carnitine is present in tissues as free carnitine,
in relatively high concentrations, and as acylcarnitines. Certain clinical
conditions such as muscle dysfunction, lipid abnormalities, and intradya-
litic symptoms have been suggested to be related to dialytic losses of
L-carnitine. We studied 54 patients (36 males and 18 females; aged 25—76
years) on hemodialysis over 3 years: 70% of patients underwent bicarbon-
ate dialysis while 30% used acetate; 60% of patients were dialyzed with
biocompatible membranes and the rest with cellulosic ones. Basal levels of
serum carnitine (free, short-chain and long-chain esters), routine bio-
chemical and hematological blood parameters, anthropometric data, lipid
profile, 1Cr and Kt/V were determined prior to the administration of
L-carnitine (an i.v. bolus dose of 3—5 mg kg1 after each dialysis session).
Patients were on L-carnitine therapy for 6 months. All parameters were
reevaluated at 3 and at 6 months after starting L-carnitine supplementa-
tion. In patients with basal triglyceride values above normal, L-carnitine
significantly reduced triglyceride levels (N = 12; 347 vs. 210 mg/dl) and
increased HDL-cholesterol values (N = 12; 32.5 vs. 39.2 mg/dl, P < 0.01).
Patients with normal triglyceride basal values showed no modification on
lipid profile. Supplementation with L-carnitine caused a significant rise in
PCR values (N = 45; 1,15 vs. 1.41, P < 0.05), particularly in patients
dialyzed with biocompatible membrane. Kt/V values showed no modifi-
cation. We also observed a significant increase in arm circumference with
L-carnitine supplementation (N = 45; 21.2 vs. 22.5, P < 0.05). Treatment
with L-carnitine markedly decreased the proportion of esterified carnitine
with respect to free carnitine, which may indicate more efficient catabo-
lism of both long-chain fatty acids and organic acids from Krebs cycle.
Utility of HCV 1gM anti-core antibodies in positive HCV hemodialysis
patients. J. Garcia-Valdecasas, M.C. Bemal, F. Garcia, N. Montiel, and S.
Cerezo, Hospital Universitario, Granada, Spain. This study was aimed to
evaluate the correlation between ALT levels and positive HCV 1gM
antibodies (Ab) in hemodialysis patients. In 45 blood samples (BS) from
15 hemodialysis patients with positive HCV IgG Ab (studied by immuno-
blot 2nd generation RIBA test) were evaluated HCV 1gM Ab (by ELISA
test) and its relationship with ALT levels. Were considered elevation of
ALT, levels higher than 150% upper normal limit. Three patients had
persistent elevation of ALT in BS with positive HCV 1gM. Five patients
had alternating elevation of ALT levels, and 4 of them (80%) had positive
HCV 1gM Ab. Seven patients had no elevation of ALT levels in BS; 2 of
them had positive HCV 1gM. Seventeen of the 45 BS showed elevation of
ALT levels, but only 16 had positive HCV 1gM Ab (94%). From the other
28 BS without elevation of ALT levels, only 8 of them had positive HCV
1gM Ab (28%). There was statistical difference between the mean of ALT
values from negative HCV 1gM BS compared to the mean of ALT values
from positive HCV 1gM BS (28.6 4.5 lU/liter vs. 65.4 22.9 lU/liter,
P < 0.001). There was an excellent correlation between HCV 1gM Ab
levels and ALT levels (r = 0.81). In conclusion, the presence of HCV 1gM
antibodies in sera of hemodialysis patients is related to elevation of ALT
levels, so this viral marker is an excellent indicator liver damage induced
by HCV.
Relationship between HCV 1gM anti-core antibodies and HCV RNA in
hemodialysis patients. Follow-up study during two years. .J. Garcia-
Valdecasas, MC. Bernal, F. Garcia, C. Roldan, A. Leyva, and S. Cerezo,
Hospital Universitario, Granada, Spain. This study was performed to
determine the relationship among the elevation of ALT, the presence of
HCV IgG antibodies (Ab) (immunoblot 2nd generation RIBA test), the
presence of HCV 1gM anti-core Ab (ELISA test), and the presence of
HCV RNA (PCR) in sera of hemodialysis patients. We studied 107
patients: 27 of them were positive HCV IgG Ab (25.2%), and we selected
8 patients to study the other viral markers during 2 years eveiy 2 months
[we studied 24 blood samples (BS) from these 8 patientsj with the
following selection criteria: positive Ab against c22, c33-c, 5-1-1 and
clOO-3 viral peptides, no active infection by HVA, HVB, CMV, EBV,
HSV or HIV; no hepatotoxic drugs or cholelithiasis. We considered
elevation of ALT as levels higher than 150% of the upper normal limit.
Eleven BS showed elevation of ALT (45.8%), all of them were positive
HCV 1gM anti-core (100%), but only 7 of them (63.6%) were positive
HCV RNA. There was an excellent correlation between 1gM Ab levels
and ALT levels (r = 0.81). From 13 BS without elevation of ALT, none of
them had positive HCV 1gM Ab, but 5 of them were positive HCV RNA.
There was no statistical difference between ALT levels of 12 positive HCV
RNA BS compared to ALT levels of 12 negative HCV RNA BS (53.5
28.0 lU/liter vs. 37.4 17.5 lU/liter). Conclusions: (1) HCV 1gM Ab are
related to elevation of ALT levels, and they can be used as serological
marker of liver damage induced by HCV. (2) Both ALT levels and HCV
1gM Ab were not correlated with HCV RNA in sera. (3) The absence of
HCV 1gM Ab and/or HCV RNA in blood samples of hemodialysis
patients with positive HCV IgG Ab and normal ALT levels is not
necessarily an indication of the absence of active infection by HCV.
High-flux dialysis. Impact of central and peripheral recirculation on
post-dialysis solute rebound. J. Garcia-Valdecasas, A. Navas-Parejo, M.
Manjon, and S. Cerezo, Hospital Universitario, Granada, Spain. To know
the impact of central and peripheral recirculation on post-dialysis solute
rebound, we studied 22 patients on high efficiency dialysis (high-flux
hemodiafiltration, Polysulfone 1.8 m2 x 2 in series) with a dialysis time of
180, 150, 120 and 90 minutes, carried out in 4, 8, 6 and 4 patients,
respectively. In the table are data (mean SD) of dry weight (dW),
intradialysis weight loss (delta), blood flow (Qb), extracorporeal urea
clearance (K0rca), Kt/V, total BUN (BUNt), total eliminated BUN
(BUNe), recirculation (Rec), rebound of BUN at 2 minutes post-dialysis
(BUNr2'), and total rebound of BUN at 60 minutes post-dialysis (BUNrt):
Patients dW Delta Qb
N = 4 (t = 180)N = 8 (t = 150)N = 6 (t = 120)N = 4 (t = 90)
110.6 5.1 5.2 1.2 595 40
82.4 17.2 4.1 1.4 611 43
78.8 15.9 3.9 1.7 603 33
57.2 10.0 2.6 0.5 590 35
Patients Kt/V BUNt
N = 4 (t = 180)N = 8 (t = 150)N = 6 (t = 120)N = 4 (t = 90)
507 33 1.70 0.14 43736 5529
473 73 1.59 0.28 31344 11324
479 42 1.49 0.16 30109 6272
451 58 1.68 0.15 14906b 2870
Patients BUNe Rec BUNrt BUNr2'
N = 4 (t = 180)N = 8 (t = 150)N = 6 (t = 120)N = 4 (t = 90)
34348 4439 12.4 1.1 11.3 0.6 4.1 0.5
23220 6951 10.4 2.4 12.1 4.6 4.1 2.5
22276 4403 9.2 1.1 13.7 3.3 4.9 2.2
ll7S6 2170 10.9 1.8 17.2a 1.2 6.3a 1.0
ap < 0.05; bp < 0.01 with respect to t = 180 minutes values.
The incidence of central + peripheral REC on BUNrt was 36.0 2.6%,
34.2 9.2%, 36.1 13.4%, and 36.7 8.8% at dialysis of 180, 150, 120
and 90 minutes, respectively, without statistical differences among these
different groups. Conclusions: (1) In high-flux dialysis, total post-dialysis
solute rebound increases with lesser treatment time. (2) The impact of
recirculation on solute rebound is approached during this postdialysis
rebound, and this effect is independent of dialysis time. (3) This recircu-
lation effect on solute rebound is equilibrated at 2 minutes post-dialysis.
High-flux hemodialysis: Effect of post-dialysis solute rebound on quan-
tification of dialysis. J. Garcia-Valdecasas, M Manjon, J.G. Her'as, and S.
Cerezo, Hospital Universitario, Granada, Spain. Post-dialysis solute re-
bound is higher with high efficiency dialysis. The aim of this study was to
know the dose of dialysis in patients treated with high-flux dialysis and
simultaneous diffusive and convective transports. Twenty-two patients (12
females and 10 males) with dry weight between 61.5—1 15.6 kg (mean 82.0
21.3 kg), delta 1.2—6.2 kg (mean 4.0 1.5 ky), were dialyzed with
high-flux hemodiafiltration (Polysulfone 2 x 1.8 m in series, Qb = 602
34 ml/min, Qd = 776 41 mI/mm) for a dialysis time of 90, 120, 150 and
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180 minutes (mean 136.4 30.3 mm), according to urea distribution
volume and delta. Recirculation was less than 15%. Extracorporeal urea
clearance was 447 45 mI/mm. BUN in serum was measured at different
intra- and post-dialysis (t) time (values in % of pre):
(%) Pre 2' 30' t — 30' t
BUN 100 83±6 57±7 27± 7 22±8
(%) t + 2' t + 10' t + 30' t + 60'
BUN 27±7 29±6 33±6 34±6
The quantification of dialysis was measured by KtIV (Daugirdas, ASN,
1992) and the rate of urea elimination by PRU [= 1 — (BUN X
V)pre/(BUN x V)postl. The results at different post-dialysis times were:
t t+2 t+10' t+30' t+60'
Kt/V 2.0 0.4 1.7 0.3a 1.5 03h 1.4 021, 1.3 02h
PRU(%) 81±6 76±6 74±12 71±11 70±5
ap < 0.05; bp < 0.01 with respect to t values.
We conclude that: (1) The effect of urea rebound on Kt/V is higher than
on PRU. (2) Single pool urea kinetic model does not show the urea
behavior during dialysis. (3) For adequate doses of dialysis treatment
blood samples must be measured at least 30 minutes post-dialysis time. (4)
With the high efficiency technique, an increase of dialysis time poorly
increases urea elimination.
Kinetic factors involved in post-dialysis urea rebound. J. Garcia-
Valdecasas, J. G. Hervas, A. Navas-Parejo, and S. Cerezo, Hospital Univer-
sitario, Granada, Spain. To evaluate the impact of blood flow (Qb),
extracorporeal urea clearance (Kur), and quantification of dialysis index
(Kt/V and PRU) on post-dialysis urea rebound, 22 patients with FRR =
0 and recirculation less than 15% were treated with high-flux hemodiafil-
tration. The dry weight was between 61.5—115.6 kg (mean 82.0 21.3 kg),
the delta was 1.2—6.2 kg (mean 4.0 1.5 kg) and the dialysis time was 90,
120, 150, 180 minutes (mean 136.4 30.3 mm) with respect to volume and
delta. BUN and Hct were measured predialysis, every 30 minutes intra-
dialysis, post-dialysis and 60 minutes post-dialysis, to determine Kurea,
Kt/V, PRU, and total urea rebound (RBUN). Volume was measured by
Watson equations and Qb was measured attending the inlet subatmo-
spheric arterial pressure (Garcia-Valdecasas, ASAIO 1994). Qb indicated
by machine was between 550 and 650 mI/mm (mean 602 37 mI/mm), but
Qb used in this kinetic study was between 480 and 565 mI/mm (mean 526
31 mI/mm) (P < 0.05); Kurea was between 395 and 540 mI/mm (mean
447 45 mI/mm), Kt/V between 1.25 and 2.75 (mean 1.65 0.35), PRU
between 68.6 and 88.7% (mean 77.1 5.7), and RBUN between 9.7 and
20.2% (mean 14.3 2.7%). There was an excellent correlation of RBUN
compared to Kurea (r = 0.57), to Kt/V (r 0.61), and to PRU (r = 0.65),
but there was a poor one to Qb (r = 0.44). Conclusions: (1) Blood flow has
a minimum effect on post-dialysis solute rebound. (2) The excellent
correlation between K,,r, Kt/V and PRU with total urea rebound
explains that total rebound is higher when the efficacy of dialysis is
increased. (3) Post-dialysis solute rebound is a consequence of the
intercompartmental imbalance created by the mass transfer during dialy-
sis.
Factors involved in post-dialysis solute rebound. I. Garcia-J/aldecasas,
M.J. Espigares, and S. Cerezo, Hospital Universitario, Granada, Spain. There
are different hypotheses to explain post-dialysis solute rebound (hyperca-
tabolism, interleukin 2, etc.). Recently, Schneditz (ASAIO 1993) showed
that there is a different blood flow in each body organ and this fact can
explain post-dialysis solute rebound. To determine the effect of recircu-
lation and the different blood flow of body organs on post-dialysis solute
rebound, 22 patients with FRR = 0 and recirculation at <15% were
studied with high-flux dialysis. A double pool kinetic model was studied:
urea generation G (= V + tid Ci — V- C(lh)/tid, where V = urea
distibution volume; b = rate of body water change; tid = interdialysis
time; Ci predialysis time [C(lh) = 1 h post-dialysis BUN], total
rebound, [Rtotal = C(lh) — Ci/Ci• 100] and net rebound [Rnet = Rtotal
— G]. BUN was studied pre-, 2', 30', 60', 90', t — 30', t (post), t + 0.5', t +
1', t + 2', t + 10', t + 30' and t + 60'. 0 (0.38 0.23 mg/mm), Rtotal (41.7
4.8%) and Rnet (39.5 3.6%). There was an excellent correlation (R
= 0.77) between recirculation and 2' postdialysis rebound. The 36% of
Rnet was a consequence of recirculation. The rebound between 2 and 18
minutes post-dialysis was a consequence of the equilibrium between the
blood and organs with high blood flow (40% of Rnet). The rebound
between 18 and 60 minutes post-dialysis was a consequence of the
equilibrium between the blood and organs with low blood flow (24% of
Rnet). Conclusions: (1) Post-dialysis solute rebound cannot be a conse-
quence of urea generation, because its magnitude is higher than G. (2) In
this solute rebound there are 3 different periods: (a) the imbalance
performed by recirculation (36.1%); (b) the imbalance performed by body
organs with highest blood flow (40.3%); and (c) the imbalance performed
by body organs with lowest body flow (23.6%).
Origin of divergences between extracorporeal solute clearance in blood
vs. dialysate. J. Garcia-Valdecasas, M.J. Espigares, F. Martinez, and S.
Cerezo, Hospital Universitario, Granada, Spain. It is well-known that
extracorporeal blood solute clearance (KB) is higher than extracorporeal
dialysate solute clearance (KD). The aim of this study was to carry out the
effect of inlet subatmospheric arterial pressure (Pa) and recirculation
(Rec) on KB,a, and to compare KB,,rea to KDurea. Twelve patients were
treated with conventional dialysis (CD) (Polysulfone F-6), and 14 patients
with high-flux dialysis (HAF) (high-flux hemodiafiltration, polysulfone
HF-80 x 2 in series). QB shown by machine was 264 24 mI/mm and 602
37 mI/mm and QD volumetrically measured was 498 25 mI/mm and
776 41 mI/mm, respectively. QB was modified by our equations (ASAIO
1994) with respect to Pa (QBs): QBs QB + 0.22Pa for QB <400 mI/mm
and QBs = QB + 0.3 Pa for QB > 400 mI/mm, and to recirculation (QBr):
QBs — 0.85 Rec - QBs/100). KBar, KBrurea, and KBrurea were deter-
mined using QB, QBs and QBr, respectively. For this purpose BUNa,
BUNv, Hcta, Hctv and BUNd were determined at 30 minutes of dialysis
(a = arteria,v venous, d = dialysate). Urea distribution was constant in
red cells K = 0.859.
KB Pa Rec
DC (N = 12)
HAF(N=14)
163 18
527±30
89 17
220±22
7.8 3.1
10.2±2.3
KBs KBr KD
DC(N = 12)
HAF (N = 14)
149 16
476 28
139 15b
436 21
140±14
435 23
a P < 0.05; bP < 0.01 respect to KB values; there were no statistical
differences between KBr and KD.
We can conclude that extracorporeal blood urea clearance is similar to
extracorporeal dialysate urea clearance if blood flow measured by the
machine is modified according to the inlet subatmospheric arterial pres-
sure and recirculation (central + peripheral).
The influence of urea rebound on Kt/V and its relation with the residual
glomerular filtrate (GFR). .1. Vazquez, C. Jarava, M. Salgueira, A. Lara, V
Marti, J.A. Milan, and A. Palma, Nephrology-Service, Hospital of the
University Virgen Macarena, Seville, Spain. The post-dialysis rebound in
plasma urea concentration (UR) is the result of intracellular/extracellular
urea gradients, and of differences in urea removal from the regional blood
circulations. Recently a relationship between GFR and UR has been
reported. On the other hand UR can significantly modit' the value of
Kt/V. We have studied the amount of UR (30 mm after the end of HD)
in our patients, its relation with GFR and its influence on different
formulae to calculate Kt/V. We studied 85 stable patients on hemodialysis
(HD) with good vascular access and QB 200 —300 mI/mm. Blood samples
were obtained pre-HD, post-HD, one minute after stopping the blood
pump and 30 minutes post-HD. GFR was determined in those patients
with diuresis. GFR, per cent reduction in urea concentration (PRU) and
Kt/V at 1 and 30 minutes (after HD by Jindal and Daugirdas I formulae)
were calculated. Recirculation of the flstulae (classic method) was also
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studied. Mean value of UR was 10.3%. No significant correlation was
found between UR and GFR. Patients with higher values of PRU also had
higher values of UR. Recirculation had no influence on UR.
Kt/V
1 mm post-HD
Kt/V
30 mm post-HD P
Daugirdas I 1.3 0.23 1.18 0.2 0.05
Jindal 1.43 0.26 1.29 0.2 0.05
P 0.05 0.05
Conclusions: Mean UR in our population on HD was 10.3%. UR and
GFR were not related in these patients. Higher PRU correlated signifi-
cantly with higher values of UR (more efficient HD equals higher UR).
UR significantly modified the Kt/V. Kt/V by Jindal at 30 minutes is not
different to Kt/V by Daugirdas I at 1 minute after HD. Kt/V was not
influenced by recirculation in this study.
Decrease in prevalence of hepatitis C virus antibodies (anti-HCV) in
hemodialysis patients. Isolation measures. L. Palomares, J.A. Sobrado,
A.J. Perez, L. Cuifla, MA. Courel, I. Glez DIaz, B. Pazos, L. Glez Rodriguez,
and M. T Glez. Del Blanco, IVephrology Service, Serology Section, Hospital
Xeral de Vigo, Pizarro, Spain. We reviewed the prevalence of anti-HCV in
2 cohorts of patients undergoing maintenance hemodialysis (HD) in the
years 1990 to 1993. The outcome of the cases on HD in 1990 until
December 1993 was studied. The detection of serum anti-HCV by the
ELISA technique was initiated in May 1990. Since March 1992, the
anti-HCV positive HD patients were dialyzed on reserved machines inside
the general dialysis room. Of a total of 40 patients with an age of 52 15
(X SD) years and a rate of males/females of 1.5, on HD in 1990, 12
(30%) were anti-HCV positive. The duration of HD was higher in the
seropositive than in the seronegative patients, 99 62 vs. 42 28 months
(P < 0.01). The blood transfusion rate was over 90% in both positive and
negative patients. The only 2 hepatitis B positive patients were also
anti-HCV positive. The frequency of hepatitis B core antibodies was
higher in the anti-HCV positives than in the other patients, 75% vs. 18%
(P < 0.05). Clinical outcome was asymptomatic in all cases. Persistent
hypertransaminasemia was observed in 2(17%) cases. Six (50%) remained
stable on HD, 2 (17%) received a renal transplant, and 2 died due to
non-hepatic causes. Death rate was not different between anti-HCV
positive and negative patients, 17% vs. 11% (P> 0.05). In 1993, of a total
of 44 HD patients, 8 (18%) were anti-HCV positive. There were no new
anti-HCV cases. Blood transfusion rate remained over 80%. In conclu-
sion, a decrease in the prevalence of anti-HCV HD patients was observed.
There was no incidence of new seropositive cases. We consider that
isolation measures of HD patients in reserved HD machines could have an
important influence in obtaining these favorable results.
Evaluation of the nutritional status (NS) of anti-HCV positive patients
on hemodialysis. E. Armada, A. Otero, J. Esteban, and C.H. Cristal,
Hospital Pihor, Orense, Spain. The NS influences the morbidity and
mortality of hemodialisis patients. To assess the NS, we have recom-
mended a biochemical, anthropometric, inmunologic, and nutritional
approach (Pcr normalized, assumed equal to dietary protein intake in
hemodialisis). We prospectively studied, during a year, the NS of anti-
HCV positive patients in our unit: 5 patients, males, anti-HCV (ETA, LIA
III), age 56.2 15.4 years, time on hemodialisis 53 65.8 months.
Control group (CG): 10 patients, HCV (—), males, (age 60.5 9.9 years;
time on hemodialisis 26.7 17.6 months; P = NS). All patients received
dialysis with biocompatible membranes, without acetate, and there were
no significant differences in: Kt/V (1.06 0.15 vs. 1.11 0.26), Kru (0.6
0.9 vs. 1.6 1.8), pre-HD CO3H (21.4 1.5 vs. 22.2 2.3), Htc (31.2
4.3 vs. 30.5 3.8), and iPTH (242.1 73 vs. 104.2 85.4) (aliP = NS).
Both groups had similar body fat (triceps skinfold 9.8 3.7 vs. 10.9 2.9;
subscapular 16 6.5 vs. 11 4,4), albumin levels (4 0.2 vs. 4 0.2), and
transferrin (195.5 27.1 vs. 198.6 50.9). But anti-HCV (+) had less
muscle mass (87.6 10.3 vs. 95.2 7.8), lower total cholesterol (171.4
21.6 vs. 189 30.9), lower C3 (82 5.8 vs. 98.5 13.5) and lack of
response to hepatitis B vaccine (0% seroconversion vs. 55%) (P < 0.01),
and presented higher 'Crn (1.5 0.3 vs. 1.1 0,3), TAC (78.7 10.1 vs.
65.1 13.2) and /32 microglobulin levels (45.7 12.5 vs. 34 13.7) (all
P < 0.01). In conclusion, anti-HCV (+) patients on hemodialisis present
a lower immune response and an increased degree of protein catabolism,
characterized by raised Cra and TAC, with decreased muscular mass. In
these patients the Cr should not be used as an index of the dietary
protein intake.
Carnitine deficiency, nutritional status and dyslipemia in dialysis vs.
functioning kidney transplanted patients. AM. Castelao, A.M. Pita, C.
Fiol, M. Farriols, E. Andrés, f.M. Grinó, N. Viigili, M.P. Portabellas, M.J.
Castineiras, I. Hurtado, V Gracia, and J. Alsina, CSUBellvitge, University of
Barcelona, Barcelona, Spain. Carnitine deficiency in dialysis patients is a
potential cause of lipidic disturbances. General biochemical parameters,
free carnitine, lipid profile, and anthropometric measurements [body mass
index (BMI), triceps skinfold thickness (TST), arm muscle circumference
(AMC) were determined in 36 patients, divided into 3 groups (6 males
and 6 females in each group): GI (12 HD), GIl (12 CAPD) and GIll (12
functioning allograft, RT).
HD CAPD RT
Age 60 15 57 16 42 10
Follow-up, months
BMI, kg/bw/m2
45 14
22.3 1.4
27 9
24.1 2.3
26 11
23.7 2
S. albumine, glliter 37.5 4.5 35.8 3.4 39 3
AMC 24.2 2.1 25.7 2.6 26.6 2.9
F. carnitine mg/liter 4.02 1.21 5.18 1.54a 6.49 1.15
T cholesterol, mmol/liter 4.16 1.46 5.61 1.4k' 5.34 iT'
Triglycerides, mmol/liter 1.08 0.35 2.09 0.36 1.49 0.78
HDL-cholesterol, mmol/liter 1.08 0.35 1.03 0.25 1.06 0.33
LDL-cholesterol, mmol/liter 2.61 1.41 3.69 lOT 3.09 0.8
Apo Al, glliter 1.05 0.23 1.38 0.35a 1.27 0.33a
Apo B, g/liter 0.79 0.21 1.07 0.28 0.89 0.16
Apo C3 42.8 16 54.3 l6 47.5 19k'
Lp (a) 33.4 36" 29.2 2T' 13.4 21
a abnormal value. We have observed a positive correlation between
low-carnitine level and increased apo C3 and Lp (a) levels. We conclude
that carnitine deficiency could be induced by interfering LPLipase activity
or an increase in Lp (a) levels, contributing to the lipidic metabolism
disturbances in dialysis patients.
Residual renal function (RRF) in chronic hemodialysis (CHD): A
prospective study. E. Armada, J. Esteban, A. Otero, and C.H. Cristal,
Hospital Pihor, Orense, Spain. The relevance of preserving RRF has
recently been established in CAPD patients but not in CHD patients. We
studied 49 CHD patients, without associated catabolic factors, dialyzed
with biocompatible membranes (AN69, PPMA), bicarbonate buffer, with
a follow-up of 12 months, evaluating their RRF, nutritional status (NS)
(anthropometric and biochemical parameters), urea kinetic modeling,
lipid profile, /2 microglobulin (/32m), baseline Al, 1,25 vit D3, iPTU, EPO,
antibody response to hepatitis B vaccine (HBv), and morbidity. There
were 26 patients with significant RRF (2.4 1.4 mI/mm) (group A) and 17
without it (0.1 0.2) (group B, P < 0.01). There were no significant
differences in the Htc (30.7 4.5 vs. 30.2 3.9), pre-HD bicarbonate
(21.6 2.9 vs. 22.1 1,9), iPTH (240 333 vs. 185 259), 1,25 vit D3
(9.3 6,1 vs. 8.1 4.6), and EPO levels (14.4 13.2 vs. 18.8 17). We
observed in group A higher 'Cra (1.2 0.3 vs. 1.03 0.3) (P < 0.01) and
TAC (76.1 15.9 vs. 64.4 23.6) (P < 0.01), although they received a
lower dialysis dose (Kt/V 0.84 0.2 vs. 0.93 0.1) (P < 0.01). Group A
also showed lower atherogenic ratio (4.6 1.2 vs. 5.4 1.9), lower
baseline Al (26.7 21.3 vs. 43.2 26.9) and f32m (26.1 7.3 vs. 36.4
12.8) (all P < 0.01). The group A response to HBv was better (60%
seroconversion vs. 37%), and these patients were less likely to require
hospitalization (mean 0.11 stays/year and 1.1 days/year vs. 0.47 and 4.0). In
conclusion, low degrees of RRF influence the NS, inmune response,
atherogenic risk and morbidity of CHDp, so efforts should be made to
preserve it.
Dual jugular vein catheterization with silicone made catheters. G.
Maté, M. Vallés, J. Bronsoms, P. Torguet, and J.M. Maur Nephrology
Service, Hospital "Dr. Josep Trueta," Girona, Spain. Presently, the increas-
ing age of CRF patients who are introduced to HD has induced more
difficulties in obtaining good blood access. The jugular vein catheterization
with two silicone catheters emerging in the pectoral area of the chest after
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tunnelization has been proposed as an alternative long permanence blood
access. In order to determine the effectiveness over time of these silicone
catheters, their permeability and hemodynamic conditions have been
evaluated in 18 pairs. Eighteen pairs of silicone, X-ray opaque, catheters
of 30—40 cm of length (internal diameter 2 mm and external diameter 3.2
mm) were implanted in 18 hemodialyzed patients (12 women and 5 men).
The access blood flow ranged 300 mI/mm (275—300) and the venous
pressure ranged 140 (30—190). All but one catheter has remained opera-
tive since their implantation. The only catheter removed was because of
sepsis and thrombosis. In the remaining 17, only 3 episodes of sepsis—all
in the same patient—were observed. The life span observed ranged 18
months (2—45). These results may give support to other reports as they
suggest that good hemodynamic conditions, long life and low frequency of
infective events are obtained by using this type of blood access.
Hepatitis B(HB) immunization in non-responder HB vaccinated pa-
tients: Revaccination and human recombinant interleukin-2 (HrIL-2)
effects. J. Piera, J. Bronsoms, M. Cuirart, P. Lopez, M. Matas, G. Maté, J.M.
Mauri, R. Pascual, J. Prim, R. Sans, D. Serra, and M. Vallés, Hospital "Dr.
Josep Trueta, " Girona, Spain. Hepatitis B vaccination in healthy individuals
is currently effective (95—100%). The response rates in hemodialyzed
patients are lower (60—80%). Revaccination in healthy non-responders is
commonly successful at the same rate as seen in primovaccinations, but its
effects and the dose-effect relationship on hemodialyzed non-responders
are poorly understood. In a ten patient study, it has been suggested that
natural human interleukin-2 might improve the response rates in hemo-
dialyzed non-responders. The aim of this study was to know the effects of
vaccination, its dose related response rates, and search for the potential
advantages of the simultaneous HrIL-2 administration to obtain HB
serum antibody levels higher than 10 U/liter. Forty HD non-responder
patients have been studied. All of them had received 3 or more doses. In
10 cases the doses were of 20 g each, and in 30 cases the doses were 40
j.g. For this assay each patient repeated the vaccination protocol. Twenty
randomly selected patients from both groups received HrIL-2 (5.10 U)
administered at the precise site of the vaccination but 4 hours later. The
results have been analyzed by the chi-square technique for categorical
variables with Yates correction for two by two tables and Fisher's exact
test. In 22 patients (55%) titers of HBsAb higher than 10 U/liter were
detected at the end of the study. Responders and non-responders were not
different when matched for age, sex, weight, HCV positivity or EPO
administration. The response rate was higher in those patients receiving 40
rg per dose (66.7%). Patients under HrIL-2 responded more to the
revaccination than did the group under vaccination alone, but this
difference was found not statistically conclusive (P = 0.056). We may
conclude that revaccination, particularly if applying doses of 40 j.rg, is
effective for immunizing non-responder HD patients. Statistically, differ-
ences in favor of a HrIL-2 facilitation could not be clearly demonstrated.
Low molecular weight heparin decreases hemodialysis hypertriglyceri-
demia. C. Bemis, J. Motellon, M. Cruz Cardenal, E. Gruss, P. Sanz, E.
Muñoz, J.A. Sanchez-Tomero, G. Barn!, V. Alvarez, andf.A. Traver, Se,vicio
de Nefrologia Hospital de Ia Princesa, Universidad Autonoma, Madrid,
Spain. The incidence and degree of uremic hypertriglyceridemia in
hemodialysis (HD) can be exacerbated by the use of unfractionated
heparin (UFH). The increase in triglyceride rich remnant partides in this
population is thought to be particularly atherogenic. Low molecular
weight heparins (LMWH) are poorer stimulants of lipolysis than UFH and
may have potential advantages. Thirty new patients starting HD were
randomly assigned to treatment with either UFH or LMWH (enoxaparin).
We study lipids (trigylceride, cholesterol, HDL-cholesterol, Apo A1 and
Apo B) at one, six and twelve months. Paired and unpaired Student t-tests
was used for statistical analysis. Triglycerides on the UFH group were
203.7 92, 205.6 80, and 201.7 72, (P NS). Triglycerides in the
LMWH group were 189.4 79, 173.3 90, and 144 81 (P < 0.05). For
the LMWH the changes from month 1 to month 12 were: Cholesterol:
191.4 40, 195.8 37 (P = NS); HDL-Chol: 34.9 11.1, 35.4 12 (P
= NS);Apo A: 128 24.5, 129 25.4 (P = NS);Apo B: 103.3 24, 110.6
24 (P = NS). Patients on LMWH (enoxaparin) show a significant
decrease in triglycerides after 12 months treatment that is not seen in
patients that received UFH; therefore, LMWH may provide a clinically
superior alternative to UFH in hemodialysis hypertriglyceridemia.
The urea reduction ratio (URR) during hemodialysis is a good param-
eter to measure dialysis adequacy. V.C. J7alverde, and E.M. Bosque,
Servicio de NefrologIa, Hospital de Elda, Alicante, Spain. Among the
different parameters used to measure dialytic adequacy, we have identified
two that in our chronic dialysis patients had correlated well with the lowest
rate of morbility: PCR 1.4 and URR higher than 60% and Kt/V much
higher than 1. Our aim consisted of finding the rates of Kt/V that would
allow us to obtain the rates of PCR and URR mentioned above.
Therefore, from among 297 patients on CHD longer than one year, we
identified 47 with a high permeability membrane and 63 with cuprophan
(Cup), who, in the three consecutive twice-monthly tests had a PCR lower
than 1, a URR less than 50%, and Kt/V of or above 1. In all of them we
increased dialytic effectiveness by increasing the blood flow (Qb max =
390/ml/m), the membreane surface, (s. max. 1.9 m2), and time (T max: 270
mm). The initial membrane was retained in all cases. After one year, 87%
of the patients with HPM and 73% with Cup reached a PCR of 1.4 with
a URR higher than 60% and only a slight increase in Kt/V: 1.6 in Cup and
1.19 in HPM. An increase in time was required in Cup (270 Cup and 210
HPM). The improvement in PCR was associated with an increase in serum
albumin from 3.1 to 4.0 g/dl for Cup, and 3.5 to 4.4 for IIIPH. Conclusions:
Kt/V alone is a parameter of little value. Revelant changes in the dialysis
prescription caused only a slight increase in Kt/V. The main aim must be
to achieve appropriate nutrition and a PCR of 1.4 accompanied by a rate
of albumin higher than 4. URR alone seems to be an appropriate
parameter to measure the adequacy of hemodialysis sessions, although it
must be higher than 60%.
Angiotensin-converting enzyme inhibitors (ACE1) can worsen anemia
and increase the need for erythropoietin in chronic hemodialysis patients.
V Valverde, E. Bosque, Nefrologla, Hospital de Elda, Alicante, Spain. It has
been reported that ACEi worsen the anemia caused by renal failure and
that they may correct the erythrocytosis in patients with transplants. In
order to corroborate these remarks in terms of CHD patients, we reviewed
the histories of 296 stable CHD patients that had undergone treatment for
longer than six months: 210 (71%) received EPO, 123 (58% a dosage
lower than 150 U/kg/week, group A) and 87 (41%) had dosages higher
than 150 (group B). From group B, 51 were medicated antihypertensives;
23 of them were administered ACEi (4 associated and 19 ACEi alone).
These 23 patients are represented in this study. Seventeen of them showed
normal ferritin, absence of hemolysis, losses, HPT or aluminum poisoning.
The other 6 were excluded for exhibiting one or more of these factors. In
the other 17 patients PRA was studied, changing ACEi for Ca antagonist
alone or associated with labetalol.
Time
0 1 4 6
Hematocrit
Hemoglobin
PRA
EPO dose
32.1
10.7
9.4
255
31.3
10.4
235
32.3
10.7
173
30.9
10.3
7.5
165
A progressive fall in EPO needs was observed in 13 patients. After
months, only 4 of them required doses high than 200 U/kg/week; the
consumption of EPO went down by 35%. PRA dropped slightly after six
months. The mechanims by with the ACEi worsen anemia or increase
EPO needs is unknown, although we might speculate about of the
participation of renin. When other causes have been excluded, the EPO
needs are high and the patients are administered ACEi; therefore, its
substitution must be considered.
Antineutrophil cytoplasmic antibodies (ANCA) in hemodialysis pa-
tients: An immunologic marker of small interest? F..!. Borrego-Utiel, MC.
Perez-Miranda, MJ. GarcIa-Cortés, M.C. Sánchez-Perales, P. Serrano, MC.
Ruiz Olmo, A. Liébana, and V Perez Baflasco, Servicio de Nefrologla y
BioquImica, Hospital General de Especialidades, Jaén, Spain. Patients and
methods: Antineutrophil cytoplasmic antibodies (ANCA) were sought in
140 hemodialysis patients [78 (55.7%) males, 58 15 years old and 54
50 months on dialysis]. ANCA were determined by indirect immunofluo-
rescence in serum of the first session of three weekly dialysis and using
neutrophil fixed with ethanol as substrate. Results: Thirteen (9.3%)
patients were ANcA+, 11 ANCA-p+ and 2 ANCA-c+, with titers
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between 1/20—1/80; one patient had 1/640. All patients were asymptom-
atic, but one patient suffered massive pulmonary hemorrhage. Nephrop-
athy causing end-stage renal failure was varied among ANCA+ patients (2
renal polycystic, 2 necrotizing glomerulonephritis, 2 systemic lupus ery-
thematosus, 2 reflux nephropathy, 1 scleroderm, 1 chronic interstitial
nephropathy, and 1 unknown). Antinuclear antibodies were positive in 3
(27%) ANCA-p+ and 1 (50%) ANCA-c+ patients. ANCA were not
related with age, gender, type of membrane of dialysis, number of
transfusions, blood and HLA groups or with nephropathy. In three
patients ANCA+ accompanied polyclonal hypergammaglobulinemia.
One patient with a necrotizing glomerulonephritis had a massive pulmo-
naiy hemorrhage who required steroids and cyclophosphamide bolus and
plasmapheresis as treatment, with successful results. This patient had two
relapses in one year when cyclophosphamide was spaced to a three
monthly bolus protocol. In the second relapse ANCA were negative. A
patient with 1/640 titers had a scleroderm with minimal cutaneous lesions
and he has been asymptomatic for a long time. In this patient the rest of
the immunologic determinations (anti-GBM, anti-Sc170, antimicrosomal,
antimitochondrial, circulating immunocomplexes, etc.) were negative,
including PR3 and MPO ELISA. When we repeated ANCA determina-
tions after 8 months to ANCA+ patients, we were surprised by the
absence of ANCA positivity, but one patient had persisted with 1/1280
titers (the patient with scleroderm). Conclusions: (1) Among hemodialysis
patients there exists a low proportion of ANCA+ (9.3%), especially
ANCA-p. (2) ANCA was present without relation to base nephropathy,
age, time or dialysis parameters. (3) Sometimes ANCA coincides with
polyclonal hypergammaglobulinemia. Could it be secondary to an unspe-
cific immunologic activation? (4) ANCA is present in some patients,
associated with necrotizing glomerulonephritis and pulmonary hemor-
rhage, but most of the ANCA+ patients are asymptomatic. (5) We must
determine ANCA specificity with ELISA if we want to discover the true
meaning of these autoantibodies in the dialysis population.
Isolation of anti-HCV positive patients in the hemodialysis setting: Is it
worthwhile? MD. Arenas, C. Gonzalez, R. EnrIquez, J.B. Gabezuelo, A.
Antolin, and A. Reyes, Hospital Universitario de Elche, Alicante, Spain.
Prevalence of antibodies to hepatitis C virus (HCV), within our hemodi-
alysis (HD) unit, rose to 25.5% in 1991 and to 34.4% in 1992. Most of the
anti-HCV positive cases (72%) also had abnormalities in serum transam-
inase values. During 1992, we conducted a study that showed a close link
between two HD machines (machine 1: rr 6.8, P = 0.01; machine 7: rr 32,P = 0.0001) and anti-HCV seroconversion. To find out whether isolation
of anti-HCV positive patients could reduce the incidence for HCV
seroconversion, we split our HD unit into two separate areas with different
HD machines and staff members. Bimonthly screening for liver enzymes
and serologic markers of HCV (ELISA 2 and INNO-LIA) was performed
in 25 anti-HCV negative patients. Results: In 1993, three patients (6.6%)
became seroconverters; in fact, no seroconversion for HCV has been
detected over the last seven months. After the 12-month isolation period
the current incidence for HCV seroconversion has fallen significantly.
1991 1992 1993
Incidence 14.2% 13.9% 5% (P = 0.006)
Prevalence 25.5% 34.4% 38%
Conclusion: This report suggests that isolation of HCV positive hemodi-
alysis patients may be useful in reducing the incidence of HCV infection.
Hepatitis C virus transmission in hemodialysis. M.D. Arenas, C.
Gonzalez, R. EnrIquez, J.B. Cabezuelo, J. Lacueva, and A. Reyes, Hospital
Universitario de Elche, Alicante, Spain. This work was undertaken in order
to assess the role of blood transfusions and dialysis machines on hepatitis
C virus (HCV) transmission in hemodialysis (HD) patients. For this
purpose, we prospectively studied 50 hemodialyzed patients (with anti-
HCV negative and normal ALT levels at the beginning) throughout an 18
month follow-up period. HD duration, rate of blood transfusions and HD
machines (8) were evaluated. Serum levels of ALT and AST, HB5Ag,
HBsAc and HBcAc were checked every 2 months. Serologic markers of
HAV, CMV, HSV, EBV, and HCV (ELISA 2 and INNO-LIA) were
tested twice a year, and monthly when ALT levels were increased. Results:
Eleven patients (22%) became anti-HCV positive (3 cases with normal
ALT levels). Anti-HCV positive patients had a significantly longer length
of time on HD (86 33 vs 45 37 months, P = 0.003) and also more
transfusions (13.4 11 vs. 5.7 9, P = 0.05) than anti-HCV negative
patients. Two HD machines were risk factor for HCV seroconversion:
machine I [relative risk (rr) 6.8, P = 0.01] and machine 7 (rr 6.9, P = 0.03).
This last one was a strong risk factor (rr 32, P = 0.0001) for five anti-HCV
positive patients who had not been transfused at all from at least two years
prior to ALT elevation. Conclusions: This report shows that time on HD,
blood transfusions and dialysis machines were risk factors for HCV
transmission in HD patients.
On-line urea monitor (UM): A new approach in dialysis prescription. S.
Tallon, G. Hemdndez, A. Martmn-Malo, MA. Alvarez-Lara, R. Perez, M.
Espinosa, and P. Aljama, Hospital Universitario Reina Sofia, Córdoba,
Spain. The UM might be a new alternative to prescribe the dose of
hemodialysis (HD) therapy based on urea monitoring measurements in
the spent dialysate (D). The aims of this study were to assess the reliability
of UM (Biostat 1000) in the HD prescription and to compare UM
dialysis parameters with those calculated according to conventional meth-
ods of urea kinetic modeling. Twenty-two patients on HD were studied.
HD schedule was kept constant during the study. Blood samples were
taken at the start and at the end of HD. Urea was simultaneously
determined in D at 30 and 120 minutes by UM and by an autoanalyzer.
Total urea removal (TUR) recordered by UM was compared to the total
D collection. V was calculated according to Watson's formula (VWat), %
body weight (V%) and by UM (Vum). A good correlation between the
two methods of urea determination on D was found (r = 0.92, P < 0.001).
Furthermore, TUR by UM and total D collection were highly correlated
(17.9 7.4 vs. 17.5 7.4 g, r = 0.99, P < 0.001). Significant differences
between Vum and V% (30.6 7.9 vs. 35.2 9.6 1, P < 0.001), and VWat
(36.3 5.4) were observed. However, Vum was correlated with both V%(r = 0.75) and VWat (r = 0.72). The Kt/V by UM (1.30 .21) was
correlated with:
Kt/V r P
Kt/V Gotch & Sargent
Kt/V Daugirdas
Kt/V Jindal
Kt/V Basile
Urea reduction ratio
1.19 .18
1.39 .15k
1.54 .18
1.30 .12
0.75
0.81
0.76
0.76
0.76
<0.001
<0.001
<0.001
<0.001
<0.001
ap <0.001
We conclude that UM is an accurate method to measure the TUR by HD
and it is a reliable tool to assess the actual delivered dose of dialysis.
Renal tumors in dialysis patients. Clinical characteristics, diagnosis
and evolution. J. Almirall, C. Mallofre, J.R. Ayuso, f.M Campistol, J. Soler,
and J. Lopez-Pedret, Nephrology Unit, Consorci Hospitalari Parc Tauli,
Sabadell; Pathology, Radiology, Renal Transplant Unit, and Nephrology
Services, Hospital Clinic, Barcelona; Neprology Unit, Centre Hospitalari de
Manresa, Spain. It is well-known that dialysis patients are at a greater risk
to develop renal neoplasms, especially when acquired polycystic kidney
disease (APKD) is present. Its potential malignancy is controversial. In the
present study we review the clinical, radiological and evolutionary char-
acteristics of the renal tumors detected in a known population undergoing
dialysis treatment. During the period 1984—1992, with 587 patients/year,
12 renal tumors were diagnosed in 11 patients (8 men, years in dialysis: 4.5
3.2). Presenting form: (a) incidental Rx diagnosis while exploring other
pathologies (25%); (b) Rx diagnosis in a directed study protocol (25%);
(c) tumor-related clinical manifestations (50%): macroscopic hematuria
(3); metastatic dissemination (2); hypercalcemia (1). The incidence has
been 2.2/1000/patients-year. Ultrasonography detected the tumor in 75%
of cases; and CT in 91%. In 73% of cases, APKD was present in the
pathological exam. Clinical evolution: 5 patients (45%) are free of disease
after a 3.7 1 year follow-up (corresponding to a and b presenting forms);
3 patients (27%) are dead, due to unrelated causes; 4 patients (36%) died
in 16.5 10 months by metastatic dissemination (corresponding to c
presenting form). Conclusion: This confirms the greater incidence of renal
tumors in dialysis patients, being prevalent in males. In 73% of cases
APKD is present. Its diagnosis when tumor related symptoms are present
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carries a high mortality. We recommend US screening, especially in young
men.
DNA flow cytometric analysis as a prognostic tool in renal tumors
associated with acquired polycystic kidney disease..!. Almirall, C. Mallofre,
J.M. Campistol, J. Muntané, J. López-Pedret, and A. Cardesa, Nephrology
Unit, Consorci Hospitalari Parc Tauli Sabadell; Pathology, Renal Transplant
Unit and Nephrology Services, Hospital Clinic, Barcelona, Spain. DNA
ploidy and S-phase fraction determined by means of flow cytometry (FC)
have been used as prognostic tools in many human neoplasms. Dialysis
patients represent a high risk group for developing renal neoplasms;
however, the potential malignancy remains controversial. The aim of the
present study was to demonstrate the utility of FC DNA ploidy and
S-phase fraction in determining the aggressiveness and prognosis of this
type of neoplasm. Eleven renal neoplasms over acquired polycystic kidney
disease were included in the study. FC results were correlated with
classical prognosis factors (size, stage, histological degree) and with
clinical outcome (mean follow-up 5.5 years). All adenomas were diploid,
while the 3 aneuploid tumors corresponded to carcinomas. The mean
S-phase fraction was higher in carcinomas (7.5%) than in adenomas
(3.8%). The 3 aneuploid tumors had a poor outcome (2 died with multiple
metastases and 1 developed a contralateral renal neoplasm). All diploid
carcinomas were free of disease at the end of the follow-up. Also, the
mean S-phase fraction value was higher in the 3 cases with poor Outcome
(9.7%) than in the rest of the carcinomas (4%). In conclusion, the
determination of ploidy and/or S-phase fraction by means of FC can be
useful in determining the aggressiveness of renal neoplasms in dialysis
patients.
Venogram abnormalities associated with subclavian and jugular hemo-
dialysis catheters. A prospective study. M.P. Ruiz-Valverde, A. Segarra,
AL. Sega rra, M. Moreiras, J. Fort, J. Camps, iA. Rodriguez, J. Bartolomé, A.
Olmos, and L. Piera, Nephroiogy andAngio-radioiogy Unit, Hospital General
Universitario "Vail d'Hebron", Barcelona, Spain. Aim: To determine the
incidence of venogram abnormalities after the use of central catheters for
hemodialysis (HD) and to analyze the closely related clinical factors which
are associated with them. Patients and methods: We performed an
ipsilateral venogram in 84 HD patients (37 males/47 females) after
catheter withdrawal. Patients were aged 55 15 years. Time elapsed
between catheter removal and radiologic study was 24 27 months.
Results: We observed venous stenosis < 50% in 6 patients (7.1%), venous
stenosis > 50% in 8 (9.5%), and venous thrombosis in 12 (14.8%). The
detection of venous abnormality was unrelated to age, sex, time on HD,
indication to place the catheter, days of venous cannulation, episodes of
catheter-related sepsis, and previous episodes of arteriovenous fistula
thrombosis. According to the type of catheter, venogram abnormality
distributions were as follows: subclavian 55.5%, surgical internal jugular
(Permcath") 23.6%, and percutaneous internal jugular 10.5%. Severe
stenosis or thrombosis was present in 48.8% of subclavian and 16.6% of
surgical jugular catheters. Neither thrombosis nor severe stenosis was
observed in patients with percutaneous internal jugular catheters. Conclu-
sion: The detection of venogram abnormalities after central venous
cannulation for HD seems to be catheter-related. Neither venogram
abnormalities nor the significantly lower number of venous lesions after
percutaneous jugular cannulation can be explained by the clinical factors
we have analyzed.
Prevention of catheter-related sepsis with vancomycin in hemodialysis
patients: A prospective randomized CRS-control study. MP. Ruiz-
Vaiverde, A. Segarra, J. Fort, J. Camps, J. Bartolomé, A. Olmos, and L. Piera,
Nephrology Unit, Hospital General Universitario "Vail d 'Hebron ", Barce-
lona, Spain. Aim: To analyze in a prospective randomized study the
effectiveness of local vancomycin in the prevention of catheter-related
sepsis (CRS) in hcmodialysis patients. Patients and methods: Fifty-eight
internal jugular catheters (43 by puncture and 15 surgical catheters) were
placed in 58 patients on maintenance hemodialysis. They were randomly
separated into: Control Group: 33 patients (21 males/12 females), aged 59
15 years, 23 subcutaneous and 10 surgical catheters, catheter duration
76 days (3—299 days). The catheters were maintained only with 1% sodium
heparin; Study Group: 25 patients (13 males/i2 females), aged 59 13
years, 20 percutaneous and 5 surgical catheters. Median catheter duration
was 105 days (14—388 days). After each HD procedure, a solution of
vancomycin with 5% sodium heparin was injected in each catheter lumen
(vaneomycin concentration 100 .rg/ml). Patients were considered to have
CRS when they developed unexplained fever and/or clinical signs of sepsis
in the absence of documented infection, with blood and quantitative
catheter cultures positive to the same microorganism. Results: In the
Control Group, we diagnosed 5 episodes of CRS (3 by S. aureus, 1 by S.
epidernidis, and 1 due to E. coli). No episodes of CRS were diagnosed in
the Study Group. Cultures of the removed catheters were positive in 80%
of the Control Group and in 41.1% of the Study Group. Conclusion:
Although more data are necessary, our results seem to indicate that the
endoluminal antibiotic prophylaxis of jugular catheters with vaneomycin is
useful to prevent episodes of CRS both in percutaneous and in surgically
implanted catheters. However, this procedure was not successful in
preventing catheter colonization.
Treatment of hemodialysis catheter-related sepsis with systemic and
local endoluminal vancomycin: Long-term follow-up. MP. Ruiz-Valverde,
A. Segarra, J. Fort, J. Camps, J.A. Rodriguez, J. Bartolomé, A. Olmos, and L.
Piera, Nephrology Unit, Hospital General Universitario "Vail d'Hebron",
Barcelona, Spain. Aim: To determine the appearance of late complications
after the long-term follow-up of hemodialysis patients treated for episodes
of catheter-related sepsis (CRS) without catheter removal. Patients and
methods: Twenty-six episodes of CRS were diagnosed in 19 hemodialysis
patients with a surgical jugular catheter. They were treated with systemic
and local endoluminal vancomycin or ciprofloxacin according to a previ-
ously described method. Subsequently, the clinical evolution of these
patients was followed for a mean time of 27 months (3—44 months). In 20
eases we performed an ipsilateral venogram after catheter withdrawal.
Results: The isolated bacteria were: S. epidermidis (8); P. aeruginosa (8); S.
aureus (5); S. epidermidis + P. aeruginosa (1); and others (4). All episodes
of CRS resolved without catheter removal, with negative quantitative
cultures at the end of the treatment. The mean time elapsed between CRS
treatment and catheter withdrawal was 80 days (8—216 days). In 17 cases
the catheter was cultured, showing positive result in 5 cases, all due to P.
aeruginosa. We did not diagnose any ease of endocarditis or late septic
manifestations. Among the treated patients, 9 died from non-infectious
causes, 3 had a functioning kidney transplant, and 7 remained on
hemodialysis. Conclusion: The treatment of episodes of CRS in hemodi-
alysis patients with systemic and local endoluminal antibiotic allows us to
extend their duration without late septic complications. In 80% of the
investigated cases, the phlebographic study was normal.
Treatment of hyperkalemia in dialysis with fludrocortisone (FDC). A.
Garcia Aznar, J. Soler, J. MOdoi, and MA. Palos, Centre Hospitalari i
Cardiolbgic de Manresa, Manresa, Spain. Objective: To assess the thera-
peutic usefulness of FDC in the treatment of hyperkalemia in dialyzed
patients. Materials and Methods: We determined the potassium (K) levels
in plasma in all the patients of our departement and we chose those with
values over 6.5 (N = 28). In these patients we ordered a weekly ionogram
in plasma for up to 4 weeks, including in this study all the patients without
potassium levels under 6 and medium potassium values over 6.5 (N = 11).
The range was 6.5—7.4. We administered 0.1 mg of FDC p.o. at the end of
each dialysis and measured the K weekly during 12 weeks. After this, the
dosage was raised to 0.2 mg in the patients with no response. Results: (1)
All the patients got better [7/11 0.1 mg and 4/11 with 0.2mg (range 5.3—6.6
and decrease of 0.4—1.51. (2) In the group of patients with response to 0.1
mg, this effect began with the first month of treatment. (3) Although there
is no direct relationship, the decrease is more evident in patients with good
diuresis. (4) The major decrease is not related with initially higher levels.
(5) We didn't find secondary effects. Conclusions: (1) We believe that
FDC in useful in decreasing the potassium levels in dialyzed patients. (2)
This response is higher in patients with good diuresis. (3) The response in
anurie patients may indicate an enteric elimination. (4) The administra-
tion and the end of the dialysis warrant patient compliance.
Use of isolation of HCV+ patients to reduce the seroconversions of
HCV in dialysis units. A multicentric study in 81 centers in Spain.
Coordinators: G. Barril and J.A. Traver. Servicio de Nefrologla, Hospital de
Ia Princesa, Madrid, Spain. During two years we have studied 81 dialysis
centers in Spain, with a total of 4,516 patients in 1991 and 4,959 in 1992.
We analyzed the centers that isolated the HCV+ patients, the type of
isolation, and the global seroconversions in the second year and according
to the centers and modality of dialysis. We also evaluated the staff
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accidents suffered with patients who were Ac HCV+ and the post-
accident seroconversions. In 1991, 27 centers [8 satellite centers (SC) and
19 hospitals (H)J isolated all in monitors and only one in a special unit, and
54 centers did not isolate (15 SC and 39 H). In the second year 29 centers
isolated (6 SC and 23 H), 2 in special units, and 52 did not isolate (17 SC
and 35 H). Four hospitals that did not isolate now isolate. In 2,536 patients
who received dialysis in centers that did not isolate, we found 89
seroconversions compared with 20 in 1,166 patients who received dialysis
in centers that isolated (P < 0.001). In the centers that isolated there are
more seroconversions in H than in SC (P < 0.05), there being no statistical
significance between H and SC in the centers that did not isolate. In the
H there are more seroconversions in a year in those that do not isolate
than in those that isolate (P < 0.01). In the SC there are more
seroconversions in one year in those that do not isolate than in those that
isolate (P < 0.001). The number of seroconversions is higher in HD than
CAPD and than in domiciliary HD. Regarding accidents, in the first year
25 were reported in 62 centers compared with 36 in 54 centers in the
second year (P < 0.01). There was only one seroconversion in each year
secondary to the accident. Conclusions: (1) There is a considerable
seroconversion rate for HCV in dialysis patients, which varies according to
the type of center. (2) There is a tendency to increase the number of
centers that isolate patients in HCV+ patients, mostly in monitors and in
two cases in special units. (3) Isolation is useful in reducing the rate of
seroconversion. (4) In spite of isolation there are differences according to
the type of dialysis center. (5) We consider that it would be of interest to
continue the study to evaluate the evolution of the units over a longer
period.
Hepatopathy through hepatitis C virus in patients on dialysis. A
multicentric study in 81 dialysis centers in Spain. Coordinators: G. Barril
and J.A. Traver, Servicio de Nefrologla, Hospital de Ia Princesa, Madrid,
Spain. We have evaluated 1,163 patients on dialysis with Ac HCV+ in 81
Spanish centers, considering their hepatic antecedents. On evaluating the
increase of transaminases in the last 5 years, 59.4% of them (691) have
shown an increase of more than 1.5 times the normal level, 816 patients
(70%) never reported having had an episode diagnosed as acute hepatitis,
while 252 (22%) have presented an episode labeled as hepatitis C. A
hepatic echography was carried out on 618 patients, being normal in 340
of them, and most of the rest showing hepatomegaly or an increase in
echogenicity, suggesting medical hepatopathy. A hepatic biopsy was
carried Out on 76 patients, with findings of normal liver in 6%, active
chronic hepatitis in 34%, persistent chronic hepatitis in 27%, and cirrhosis
in 11% of the cases. There was little incidence of other pathologies. We
also analyzed the relationship with the HBV vaccination and HBcore in
these patients, as well as the evolution of the hepatopathy, there being
only one case of death in HD due to hepatocarcinomas. Conclusion: From
this study one can see the importance of the markers of hepatopathy in
relation to hepatitis C virus, and the histological severity in the cases
undergoing biopsy, since over 50% had chronic hepatopathy.
Two years follow-up of the prevalence of HCV in 81 dialysis centers in
Spain. A national multicentric study. Coordinators: G. Barril and J.A.
Traver, Servicio de Nefrologia, Hospital de Ia Princesa, Madrid, Spain. We
studied the prevalence of HCV in 81 Spanish dialysis centers [58 hospitals
(H) and 23 satellite centers (SC)I for two consecutive years with a total of
4,516 patients in the first year and 4,959 in the second (35.42% of the total
dialyses in the Spanish EDTA, 1992). We also analyzed the differences
between the different modalities of dialysis and the incidence of HCV in
the second year. There is no significant difference between the prevalences
comparing the two years: global in HD in hospitals (HDH), in satellites
centers (HDC5), CAPD or domiciliary HD (HDD). We have also
analyzed the incidence of HCV in the different modalities of dialysis
during a year with a total rate of 3.2%, as well as seroconversions,
negativations, transplant and exitus in HCV+. We have found significant
differences between seroconversions in CAPD or HDD with respect to
HD. In the negativations there is significant difference between HD and
CAPD (P < 0.01) and between HDH and CAPD, and between HDCs and
CAPD (P < 0.05), being non-existent between HDH and HDCs. In the
sanitary staff we evaluated the prevalences in the two years, the higher
prevalence persisting in the second year in the nurses, there being a
significant difference in this group between the two years, unlike the
others. Conclusions: (1) A high prevalence for hepatitis C persists in the
second year in the units studied. (2) The incidence and seroconversions of
HCV are considerable, in spite of the low number of transfusions. (3) The
number of HCV+ patients receiving transplants, transferred or decreased,
has not made the prevalence decrease significantly. (4) Among the
sanitary staff the greatest prevalence is among the nurses. (5) It is of
interest to continue our study for a longer period in order to analyze the
annual tendencies.
Efficacy of once weekly subcutaneous administration of recombinant
human erythropoietin (rHuEPO) vs. three times a week administration in
hemodialysis. M. Lago, R. Perez-GarcIa, M.S. Garcia de Vinuesa, F. Anaya,
M. Goicoechea, M. Villaverde, and F. Valderrábano, Nephrology Depart-
ment, Hospital General Universitario "Gregorio Maranón", Madrid, Spain.
Recombinant human erythropoietin (rHuEPO) offers an effective treat-
ment in anemia of the patients on maintenance dialysis. In this study, we
assessed the efficacy in reversing renal anemia of once weekly subcutane-
ous administration of rHuEPO and we compared this schedule with the
usual one of three times a week administration. We studied 30 patients
who were stable on maintenance hemodialysis treated with subcutaneous
rHuEPO, three times a week. Patients showed stable hematocrits, serum
ferritin higher than 100 nglml, and they received iron supplementation if
required. The target hemoglobin was 10.5 mgldl. Twenty-one (experimen-
tal group, EG) out of 30 patients were treated by their habitual rHuEPO
dose and schedule, during six months; then, they went to once weekly
subcutaneous administration for the following twelve months. Nine pa-
tients (control group, CG) received three times a week subcutaneous
doses of rHuEPO for eighteen months. Six patients of EG, were excluded:
three underwent kidney transplantation, two refused to participate in the
study, and one was transferred to another unit. Two patients of CG were
excluded, one underwent kidney transplantation, and the other required
prolonged hospitalization. No statistically significant differences were
found between rHuEPO doses in the two groups during the study. Two
patients of EG required a change of schedule and an increase in rHuEPO
dose because the hemoglobin level decreased below 9 g/dl. No significant
decreases on hematocrit or hemoglobin level were found in the patients in
the EG during the study and in comparison with the CG.
Start 6 months 12 months
Htc, % EG 32.5 3.8 31.8 1.9 32.5 3
CG 31.5 1.7 34.3 4.7 33 4.2
Hb, gidI EG 10.9 1.2 10.8 0.6 11.2 0.9
CG 10.6 0.6 11.7 1.9 11.2 1.6
There were no differences in leukocyte or platelet counts, serum iron,
transferrin and ferritin levels during the 18 months of study. Once weekly
administration of rHuEPO has technical advantages, is more comfortable
and in the majority of patients is as effective as the three times a week
schedule.
Vascular access in diabetic and non-diabetic patients. M. Ram frez de
Arellano, X. de las Cuevas, M Chine, M. Fulquet, F. Latorre, and 0. Pastor,
Nephrology and Vascular Surgery, Hospital de Terrassa, Barcelona, Spain.
Objective: To describe and compare the vascular access (VA) morbidity in
uremic diabetic (DM) and non-diabetic (non-DM) patients. Material and
methodology: A retrospective study of the characteristics, complications
and duration of the VA performed on 153 patients during a period of 7
years [32 DM, 20 males, 12 females, aged 59 (28—8 1) years old, follow-up
average time: 28 months per patient; 121 non-DM, 75 males, 61 females,
aged 55 (18—82) years old, follow-up average time: 32 months per patienti.
N patients N VA
Cimino-
Radial
Brescia
Brachial
PTFE
U.E. L.E.
DM 32 67 27 32 1 7
No-DM 121 222 135 58 15 14
Results: (1) The VA working time was: DM: 17.6 months; non-DM: 25.6
months. (2) The VA loss during the first post-surgical month meant:
23.8% in DM and 18.9% in non-DM. (3) The average of VA thrombosis
in both groups was 17.6%. Regarding PTFE: 4 cases (50%) in DM and 10
(35.7%) in non-DM suffered thrombosis. (4) In DM patients distal
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ischemia post-VA was present in 10 cases (19.6%), with surgical closure
necessary in 7 of them. In non-DM patients, there was distal ischemia in
12 cases (7.8%), with ligation in 8 of them. (5) Stenosis was diagnosed by
means of clinical and angiographic criteria in VA (4.6%), in DMs, and in
14 VA (9.2%) in non-DM. (6) Three or more VAs were performed in 9
(28.1%) DM patients and in 14 (9.2%) non-DM patients. Conclusion:
Diabetic patients present more difficulty in getting a vascular access for
hemodialysis, suffer more complications involving distal ischemia and the
access survival is lower than in non-diabetic patients.
Monomelic ischemic neuropathy secondary to the hemodialysis vascu-
lar access. M. Ram frez deArellano, X. Cuevas, M. Chine, N. Fulque4 J. Va/Is
Canals, F. Latorre, and 0. Pastor, Nephrology Vascular Services, and
Electromyography lab, Hospital de Terrassa, and Hospital Sant Pere Claver,
Barcelona, Spain. Objective: Defining the clinical and electroneurographic
(ENG) characteristics of patients afflicted with monomelic ischemic
neuropathy (MIN) to the hemodialysis vascular access (VA). Materials
and methodology: A retrospective study of all VA performed in our center
was carried out, reporting 21 cases of patients with a distal ischemia
syndrome post-VA [sex: 9 males/12 females, Age: 60 (20—82) years oldi.
Associated disseases: diabetes in 9 patients and peripheral vasculopathies
in 12 of them. Clinical features, the VA type/technique and the therapeu-
tic attitude were analyzed. Motorsensitive ENG was performed on 6
patients, in both extremities (the one involved and the other one as well).
Results: Six (28%) patients presented distal ischemic syndrome within the
first post-surgical 24 hours (5 humerus-cephalic FAVI and 1 femoro-
femoralis PTFE). Surgical closure was performed on all patients in an
average time of 27 (2—90) days. There was 1 MIN out of 2 patients scanned
by ENG. Fifteen (72%) patients presented ischemic syndrome after the
first post-operative 24 hours (14 humerus-cephalic FAVI and 1 radio-
cephalic FAVI). In 6 (40%) Out of these 15 patients, AV had to be ligated
in an average time of 110 (30—210) days. The remaining 9 patients evolved
favorably during an average follow-up of 24 (2—54) months. The ENG
study carried out with 3 patients showed absence of MIN en 2 cases and
severe axonal damage in the other. Conclusions: (1) Monomelic ischemic
neuropathy secondary to VA is an important secondary effect which may
require inmediate closure of the vascular access. (2) All VA distal
ischemic syndromes should be studied through ENG in order to discard or
confirm MIN.
Antibodies to hepatitis C virus (HCVAb) in continuous ambulatory
peritoneal dialysis (CAPD). Prevalence and associated risk factors. J.L.
Górriz, A. Miguel, R. Garcia Ramón, L. Segana, J. Alvariño, C. GOmez
Rolddn, M Lanuza, J. Olivares, and J. Perez Contreras, Gnspo Levante,
Levante, Spain. A high prevalence of HCVAb has been described in
hemodialysis (ND) or transplanted patients, but there are not many
studies concerning the presence of HCVAb in patients on CAPD. We
analyzed the prevalence of HCVAb and their associated risk factors in 225
patients on CAPD followed in five different treatment centers. Presence of
HCVAb was determined by the 2nd generation ELISA-HCV test (Ortho).
As a supplementary test RIBA-4 (Ortho) was used in three centers and
INNO-LIA (Imnogenetics) in remaining two. HCVAb was detected in 29
patients (11.4%). From them, 16 cases (55.1%) showed chronic (more
than 6 months) elevation of transaminases. On the univariant analysis, the
presence of HCVAb was associated with previous HD (P = 0.034),
months on HD (P = 0.045), previous hepatitis (P < 0.001), transfusions
before entrance on CAPD (P = 0.0086), HBVAc presence (P = 0.006),
and higher age (P < 0.001). There were no statistical differences when
analyzing sex, treatment center, year of catheter implantation, months on
cAPD, transfusions on cAPD, primitive renal disease, or HBVAg
presence. The multivariant analysis showed previous hepatitis (P = 0.002),
number of transfusions before CAPD (P 0.004), months on CAPD (P
0.004), and positive HBVAc (P = 0.031) to be risk factors for HCVAb
presence. Conclusions: The HCVAb prevalence on CAPD is inferior to
that found in other treatment techniques for CRF. The presence of
HCVAb in patients on CAPD is related to situations that mainly occurred
before entrance to CAPD. This fact, together with the low prevalence
obtained, shows CAPD to be a low risk treatment modality for the
presence of HCVAb.
Neoplasic disease (ND) and hemodialysis (HD). M. Fulquet, Health
Sanitary Region No. 7 Work Group, Catalonia, Spain. Objective: To
determine the prevalence, histologic type ND, diagnosis with respect to
the start of HD, prescribed treatment and evolution of ND versus those
patients (P) without ND. Materials and Methods: Retrospective study of
all patients on HD in 4 nephrology sections and 2 dialysis units (DU) since
their opening (3—10 years) [N of P = 573; sex M/F: 329/244; age: 56 years
(14—88); time on HD: 44.7 months (0.3—225); average mortality: 30.7%].
Results: 72 ND on 64 P; 2 of them presented 2 ND, and 1, 3 ND.
Sex
(M/F)N Age, years %
Time on HD,
months Mortality
P.ND 64 65.2 (31—82) 56/44 40.9 (2—168) 43.7
P.non-ND 509 55.4 (14—88) 57/43 45.7 (0.3—325) 28.6
P.ND PRE HD (19) START (12) HD (38)
Age at start of HD 68.5 (46—78) 70 (55—82) 61.7 (31—81)
Age when ND diagnosed 64 (42—72) id 65 (36—82)
Average mortality 5 (27.2%) 4(33.3%) 19(50%)
Average mortality per ND 1(20%) 3 (75%) 11(62.5%)
ND PRE HD (19) START (12) HD (41)
Time on HD, months 26,6 (2—81) 21.5 (3—84) 49.9 (7—168)
Follow-up time, months 78.9 (6—228) Id 12.4 (1—87)
Diagnosis out of routine 5% 33.3% 36.6%
controls
No therapy 0% 16.5% 24.3%
Location, N/%
Urinary bladder 7 (36%) 1(8.3%) 2 (4.9%)
Renal/genito-urinary 2 (10.5%) 1 (8.3%) 7 (17.1%)
Dermathological 3 (15.7%) 2 (16.6%) 8 (4.9%)
Digestive — 1(8.3%) 9 (21.9%)
Respiratory — — 6 (4.6%)
Others 1(5.3%) 1(8.3%) 2(9.9%)
Conclusions: (1) Prevalence of ND was 11.16%. (2) Mortality caused by
ND is 27.3% on ND patients and means 2.7% (15/273) of the total N of
HD patients [3—46% (31/64) of ND patients have been diagnosed before
the start of HD]. (4) Diagnosis of ND at the start and/or during HD occurs
in 30% of the cases through routine controls. (5) We have not opted out
therapy, despite this being a retrospective, multicentric and no protocol
study.
Multicentric study on causes of definitive exclusion from CAPD for a
three-year periOd. J. Perez Contreras, J. Olivares, R. Garcia Ramón, A.
Miguel, J. Alvariño, C. Gomez Roldán, M. Lanuza, Grupo Multicéntrico,
Levante, Spain. We analyzed the number and causes of definitive exclusion
from CAPD which occurred in a multicentric group including five CAPD
centers for the period 1/1/91 through 12/31/93 [375 patients, 197 males and
178 females (mean age 56.8 15.4 years, mean time on CAPD of 29.8
25.0 months]. The most common kidney diseases were unknown cause
(29.4%) and diabetic nephropathy (19.1%). Prevalence of hypertension
(40.3%), age > 65 years (34.7%), diabetes (24.1%), dyslipidemia (20.9%),
and cardiopathy (18.8%) was high. During these 3 years, 185 patients
dropped out of CAPD: 86 died (46.5%), 29 were transplanted (15.7%), 28
transferred to hemodialysis after peritonitis (15.1%), and 41(22.2%) due
to other causes. One patient (0.5%) recovered renal function. The deaths
were basically due to cardiovascular, infectious not related to CAPD or
uncertain causes (patients died at home) probably due to cardiovascular
disease in a high number of cases. The analysis by years shows a
progressive decline in drop-out: 64 (29%) cases in 1991, 63 (26.1%) in
1992, and 58 (22.7%) in 1993 and a decreasing transfer to hemodialysis
(42.2%, 36.5% and 34.5%, respectively) without statistical significance.
However, the observed decrease in peritonitis rate (1.33 episodes per year
in 1991, 1.23 in 1992, and 0.96 in 1993) has allowed us to obtain a
significant reduction in the frequency of this pathology as a cause of
drop-out from CAPD: 13 (20.3%), 11 (17.5%), and 4 cases (6.9%),
respectively, P = 0.04 (chi-square for tendencies). No other differences
were found. Conclusions: Actually, patients on CAPD tend to present a
higher stability on the technique, with a significant reduction in the
transfer to hemodialysis due to peritonitis.
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Does CAPD continue to be the best dialysis method for diabetic
patients? F. Llamas, C. Gómez Roldán, L. Sanchez, M. Orts, E. Gallego, A.
Serrano, E. Andrés, and E. Olivas, Servicio de Nefrologla, Hospital General
de Albacete, Albacete, Spain. The outcome of 30 diabetic patients (from a
group of 338 who started dialysis from January 1992 to January 1994) is
presented. Twenty-six started CAPD and 4 started hemodialysis (HD).
Twenty-seven patients received CAPD for a period of time during their
follow-up, and 21 patients remained on CAPD exclusively (66.6% were
male). Mean age was 50.7 17 years (93% suffered type I diabetes). Mean
permanence time was 31.8 21 months on CAPD and 28 21 months on
hemodialysis. At the beginning of therapy 83% of patients presented
hypertension, 17% had vascular calcifications, 13.1% had peripheral
vascular disease, and 10% presented angina pectoris (2 cases had a history
of acute myocardial infarction). Laboratory data:
Baseline 1 year 3 years 5 years
SAP 146.6 142.8 129 a 142.7
DAP 85.8 85.9 72.1' 76.6
Cholesterol 227.6 236.9 l87.4' 177.la
HDL cholesterol — 38.2 42.7 39.1
Triglycerides
HbA1
152.4
7.56
163.2
7.91
145.6
7.2
189.8
9.08
Protein 6.51 6.82 6.75 6.75
Albumin 3.41 3.64 3.88 3.43
IgG
Calcium
1083
8.78
1259
9.04
1204
954
1258
9.76
PTHi 248 232 181 282
a P < 0.05 compared with baseline data; b P < 0.05 compared with data
at one year.
The peritonitis incidence was 1.08 episodes/patient/year (17 episodes in 27
patients). No significant differences were found in hospitalization rates or
mean hospital stay time between CAPD and HD patients. Coronary artery
disease incidence at 1 year remained about 25%; in contrast, peripheral
vascular disease incidence increased to 25% at 5 years (43% of patients
died and 3% underwent kidney transplantation; the totality of grafts were
well-functioning at 3 years of follow-up). Conclusions: (1) Arterial pres-
sure was properly controlled. (2) Nutritional Status S maintained at 5 years
of follow-up. (3) Serum glucose and lipid levels remained constant. (4)
Osteodystrophy did not get worse. (5) Dialysis type did not affect the
progression of vascular disease. (6) CAPD is a medium/long-term good
dialysis method for diabetic patients.
Acute renal failure due to atheroembolic renal disease (ARD). A.
Gómez, C. Mon, T Ortuho, J.M. Alcdzar, M. Praga, F. Hemández, R.
Sanchez, and J.L. Rodicio, Hospital 12 de Octubre, Madrid, Spain. Between
August 1988 and July 1993, seven cases of ARD have been diagnosed in
our hospital. The diagnosis was established by the detection of character-
istic cholesterol crystals in renal biopsy (6 cases) and funduscopic exami-
nation (1 case). Clinical data, vascular risk factors, precipitating events,
and forms of presentation were analyzed. All the patients were males; age
was 64 15 years (57—73). Regarding cardiovascular risk factors, 100%
had arterial hypertension, 100% were smokers, 57% had hypercholester-
olemia, and 28% diabetes mellitus. Precipitating events were: cardiac
catheterism (42%), vascular surgery (28%), renal arteriography (14%)
and anticoagulative treatment (14%). The interval between the precipi-
tating event and the diagnosis of acute renal failure was 1.8 months (1—3).
The most common clinical presentation was a progressive renal insuffi-
ciency (71%). Most relevant analytical data were eosinophilia (57%),
eosinophiluria (50%), proteinuria (100%), and microhematuria (66%).
Thrombocytopenia or hypocomplementemia were not observed (42% of
the patients died in the first year of follow-up; 28% required chronic
dialysis; 28% presented stabilization of renal function). In conclusion,
ARD is a non-exceptional cause of ARF in patients with severe athero-
sclerosis submitted to vascular surgery, invasive vascular explorations or
anticoagulation. The prognosis is poor, with a high mortality and without
improvement of renal function.
Microbiological diagnosis in continuous ambulatory peritoneal dialysis
(CAPD): Comparison of Bactec and Bact/Alert blood culturing systems.
F.J. Borrego Utie4 V Perez Bañasco, I. Cuesta LendInez, C. Carazo Carazo,
C. Sanchez Perales, M.J. Garcia Cortés, P. Perez del Barrio, and A. Liébana
Canada, Servicio de Nefrologia y MicrobiologIa, Hospital Genera4 Jaén,
Spain. Introduction: Peritoneal dialysate effluent contains a low concen-
tration of organisms and it should be cultured in blood culture media.
Bactec and Bact/Alert are semi- and fully automated blood culturing
systems, respectively, which monitor the existence of growing organisms,
through detecting CO2 production level once a day (Bactec) or six times
per hour (Bact/Alert). These systems show the best moment to obtain
subcultures in traditional microbiological media. Patients and methods:
Peritonitis episodes of our CAPD unit were revisited in the last 4 years,
separated into two periods: 1990—1991 (Bactec period) and 1992—1993
(Bact/Alert period). Results: Peritonitis number decreased with time and
we also observed a relative increase of gram-negative peritonitis. Positivity
rate was high with both systems (89.4% Bactec vs. 92.8% Bact/Alert),
rising to 100% in the last year with the Bact/Alert system (P < 0.05).
Bact/Alert detected microorganisms in three patients in a control culture,
several days previous to presenting some complaints. Time to detection
was shorter with Bact/Alert. There were no differences in organisms
detected with both systems. S. epidermidis was the most frequently isolated
organism followed by S. aureus. Other staphiloccoci (S. cohni4 S. auricu-
laris, S. capitis. ..) were also recovered by both systems in similar rate.
Streptoccocus and gram-negative peritonitis increased significantly.
1990 1991 1992 1993
Patients with peritonitis 25 28 28 28
Time in DPCA, months 30 25 34 28 32 29 34 33
Peritonitis, N 68 36 51 32
Peritonitis + (%) 89.7 88.9 88.2 100
Microorganisms 61 32 45 32
Gram + 58 27 27 25
S. aureus 10 4 1 4
S. epidermidis 24 16 15 7
Otros Staph. 16 4 3 7
Streptoccocus 8 3 7 6
Gram— 3 5 18 6
E.coli 2 6 1
Pseudomonas 1 1 5 3
Candida parapsilosis 1
Conclusions: (1) We observed a decrease of staphiloccocus peritonitis and
an increase of peritonitis induced by gram-negatives and streptococcus. (2)
Bactec and Bact/Alert are adequate culturing systems for detecting
microorganisms in peritonitis of CAPD patients. (3) Bactec and Bact/
Alert were found to be comparable in their capability to detect microor-
ganisms. (4) We did not observe significant differences in types of
organisms recovered by both systems. (5) Bact/Alert can be used to detect
microorganisms of CAPD peritonitis more accurately and earlier.
Acute renal failure in the elderly. Prognostic factors of mortality. 1.
Bujons, J. Fort, J. Camps, M. Martin, I Bartolome, J.A. Rodriguez, A.
Segarra, X Borrellas, P. Ruiz, A. Olmos, and L. Piera, Nephrology and
Preventive Medicine Departments, Hospital General Vail d 'Hebron, Barce-
lona, Spain. Aim: The assessment of predictive factors of mortality in older
patients developing acute renal failure (ARF). From 1986—1992, 171
patients older than 65 years old who developed ARF during their stay in
our hospital were included in the study. Information about etiology of
ARF, complications, underlying diagnosis, treatment, and laboratory
determinations was collected. Results: 57 (33.3%) of the 171 studied
patients were women; 93 (54.4%) patients needed dialysis, 90 (52.6%)
patients died. The variables chosen from the logistic regression model
were: diabetes, sepsis of abdominal origin, cardiac surgery, and the
presence of aortic aneurysm as a main illness, acute repiratory distress
syndrome (ARDS), and myocardial infarction as a complication and
oliguria as well as the low level of hemoglobin. The variables found to be
significantly associated with mortality in the final logistic model were:
ARDS, the presence of oliguria, the sepsis of abdominal origin as well as
the diabetes. We conclude that in patients older than 65 years old, the age
is not related to the mortality, while the ARDS, diabetes, abdominal sepsis
and oliguria should be considered as strong independent predictive factors
of mortality.
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Effects of calcium antagonist (Ca) in prognosis of severe acute renal
failure. MD. Ja,illo, F. GarcIa-MartIn, G. de Arriba, M Sanchez Heras, R.
Sdncez Hemdndez, A. Roman, A. Blanco, P. Carlevaris, A. Cartes, and R.
Ginestal, Nephrology Service, Hospital General Universitario de Guadala-
jara, University of Alcald de Henares, Guadalajara, Spain. The protective
role of Ca in acute renal failure (ARF) is well-known. We performed a
prospective study to evaluate the efficacy of Ca in ARF patients secondary
to acute tubular necrosis, defined as plasma creatinine  3 mg/dl or Cr 
two times basal values. We analyzed 14 patients (10 M, 4 F), with a mean
age of 61.4 15.3 years, diagnosis ATN of medical etiology (6 nephro-
toxic, 4 sepsis and 4 shock); two of them had chronic renal failure
previously. From the start of study five patients were treated with
felodipine 5 mg/day (ARF-Ca). No significant differences were observed
in blood pressure, plasma or urea creatinine, hemoglobin or hematocrit
during the evolution between ARF-Ca or ARF patients not treated with
felodipine (ARF-No).
ARF-Ca ARF-No
Duration ARF days 10.4 4 18.7 13
Basal diuresis cc/d 1154 523 957 873
Diuresis 7th day cc/d 1523 1540 1057 835
Na urine basal mEqiliter 63 42 88 47
Na urine 7th day ,nEqlliter 90 18 109 84
FENa basal % 6.8 1.5 5.7 1.6
FENa 7th day % 10.8 1.7 5.8 2.2a
ap <001
Overall mortality was 43%. Only one ARF-Ca patient died. No differences
were found in requirement of hemodialysis or continuous pump veno-
venous ultrafiltration, cardiac output, or complications secondary to ARF
between both groups. Conclusions: The use of Ca had beneficial effects on
medical causes of ARF evolution. Ca could exert effects through an early
increase of diuresis, associated with a greater excretion of filtered sodium.
FENa is the best marker of recovery in ARF-Ca.
Soluble !CAM-1 molecule during acute renal allograft rejection. T.
Bricio, M Rivera, J.M Morales, A. Molina, A. Martin, and F. Mampaso,
Pathology and Nephrology Departments, Hospital Ramon y Cajal and
Hospital 12 de Octubre, Madrid, Spain. We have measured soluble ICAM-1
(5ICAM-1) concentrations in the sera of forty-two kidney transplant
recipients (23 patients with stable graft function and 19 patients with acute
rejection), using a sICAM-1 assay ELISA during the first three post-
operative weeks in order to assess the potential usefulness of this molecule
as a possible marker of acute renal rejection. All the patients studied
showed, on the first post-transplant day, elevated serum levels of sICAM-1
(260 53 ng/ml). Interestingly, all those patients with good graft function
presented thereafter a reduction of sICAM-1 serum levels close to the
normal values (185.2 40 ng/ml). In contrast, the serum levels of
sICAM-1 were significantly increased (371.5 86 ng/ml; P < 0.001) in the
other group of patients three to four days before diagnosis of acute
rejection. Our findings demonstrate that quantitative determination of
serum sICAM-1 may be of predictable clinical value in transplanted
patients with acute renal allograft rejection.
Treatment of post-transplant erythrocytosis with enalapril. M.J. Marco,
MA. Gentil, P. Pereira, G.R. Alga rra, J.L. Rocha, V Cabello, F. G. Sierra, L.
Gil, F. Garcia-Pesquera, and J. Mateos, Servicios de Nefrologia y M Nuclear
del Hospital Universitario Virgen del Rocio, Sevilla, Spain. Introduction:
Erythrocytosis is a relatively common phenomenon following renal trans-
plantation and is associated with an increase risk of thromboembolism.
The pathogenesis remains unclear. Angiotensin converting enzyme inhib-
itors may be an effective treatment for post-transplant erythrocytosis.
Patients and methods: Fifteen patients with persistent post-transplant
etythrocytosis were treated with enalapril. Poliglobuly was defined as Hct
of 52% or greater in men and 49% or greater in women. Serum creatinine
values were 1.12 0.23 mg/dl. Nine patients received immunosuppression
therapy with prednisone, cyclosporine and azathioprine; six patients were
treated with prednisone and cyclosporine. The duration of erythrocytosis
prior to the study was about 28 20 months; at that time all of them
received anti-platelet agents and seven patients needed periodical phle-
botomy. ACE inhibitor isotope renography with ssmTcmercaptoacetyl
triglycine (MAG) was performed in all individuals in order to rule out
renal artery stenosis. Initial dosage with enalapril was 2.5 mg/day; individ-
ual adjustments were made. Results: Hct was lowered from basal values
51.8 2.8 to 48.7 4.5 in the first month (P < 0.01) and in the third
month was lowered to 45.4 4.5 (P < 0.002). All patients reached Hct
values below 50%. None required phlebotomy after starting treatment.
Neither renal function nor arterial blood pressure showed significant
changes. None of the patients developed any serious adverse effects during
the study, although two patients became anemic and suppression of
treatment was required, showing later a new increase of hct from previous
values. Conclusions: Treatment of post-transplant with enalapril is effec-
tive with minimal adverse effects. Anemia is rapidily reversed by tapering
medical dosage.
Acute renal failure (ARF) in intensive care units (ICU). Treatment and
prognostic factors. J. Lavilla, M Martin, J. Buades, N Garcia, C. Vazquez,
P. Errasti, and A. Purroy, ClInica Universitaria de Navarra, Pamplona,
Spain. Introduction: ARF is of common occurrence in ICU and represents
one of the most important problems in clinical nephrology. ARF is often
a component of multiple organ system failure in critically ill patients. The
prognosis of these patients is worsened. Methods: We present the results
of 103 patients treated for ARF between February 1992 to February 1994.
We have evaluated the treatment [conservative (C), intermittent hemodi-
alysis (IHD), and continuous venovenous hemofiltration/hemodiafiltra-
tion (CVVHF/FIDF), mortality (M), and multiple organ system failure—
cardiovascular (Cv), respiratory (R), hepatic (HP) and hematological
(H)]. Results:
N M%
C
IHD
CVVHF/HDF
61
15
27
41
33
70
0
N
1
Non-renal organ failure %
Type
>1 R CV HP HM
C
IHD
CVVHF/HDF
36
20
0
34
26
11
30 39 34 16
54 60 40 66
89 70 81 48
11
13
48
Conclusions: (1) The conservative treatment of ARF is efficient in most
patients. The dialytic treatment was employed in an important number of
cases. (2) The prognosis was worse in patients who needed CVVHF/HDF;
nevertheless, these patients had multiple organ system failure.
Chronic renal failure in liver transplant recipients. M Espinosa, E.
Fraga, A. Martin-Malo, MA. Alvarez-Lara, R. Perez, G. Hernandez, M.
Mata, and P. Aijama, Hospital Reina Sofia, Córdoba, Spain. The use of
cyclosporine (C5A) in organ transplantation has led to a significant
improvement in graft and patient survival. However, CsA therapy is
frequently complicated by nephrotoxicity, which can lead to chronic renal
failure (CRF). In this retrospective study we evaluated the effects of the
long-term CsA therapy on renal function in stable liver transplant
recipients (LTR). Fifty-four LTR with a survival of at least 2 years were
studied. Patients were divided into two groups according to the presence
(Group I); or no presence (Group II) of CRF. CRF was defined as a
maintained serum Cr level > 1.7 mgldl. Serum Cr, CsA doses and CsA
levels at 1 month, 6 months, 12 months and 24 months after liver
transplantation were analyzed. CRF was present in 16 patients (29.6%).
Age, sex, CsA doses and CsA levels were not significantly different in both
groups. The prevalence of hypertension was higher (8 1.2% vs. 36.8%, P <
0.05) in Group I. There was a significant difference in serum Cr between
both groups since the first month of liver transplantation.
Basal I month 6 months 12 months 24 months
Group I 1.1 0.9 1.4 0.5 1.7 0.6 1.9 0.4 2.3 1.0
Group II 0.8 0.2 1.0 0.3 1.0 0.3 1.2 0.3 1.1 0.3
P< 0.22 0.01 0.01 0.001 0.001
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A renal biopsy was performed in 4 cases with Cr > 2 mgldl and chronic
CsA nephrotoxicity was found in all patients. Two patients (3.7%)
progressed to end-stage CRF at 26 and 31 months after liver transplan-
tation. Chronic CsA nephrotoxicity is a common complication in LTR
which can evolve to end-stage CRF. The main risk factor was an increase
of the serum Cr from the first month post-transplant.
Sequential immunosuppression as a rescue therapy in steroid-resistant
idiopathic nephrotic syndrome. F. Martinez, I. Zamora, J. Fuentes, S.
Mendizaba4 and J. Simon, Pediatric nephrology unit, Children s Hospital Ia
Fe, Valencia, Spain. Among the 243 children with idiopathic nephrotic
syndrome (INS) controlled between 1971—1992, 51(21%) were steroid-
resistant (SR) under the following criteria: absence of remission after
standard treatment with prednisone for 8 weeks (ISKDC protocol) and
lack of response to 3 iv. boluses of methyiprednisolone (1 g/l.73 m2). The
histological pattern was: MC (21), FSGS (22) and DMP (7); 1 hemophilic
patient was not biopsied. A two-step sequential immunosuppressive
treatment was administered to 42 cases: a first step with CFM (2.5
mg/kg/day) for 8 weeks, and since 1986 after CFM had failed, a second
step with CsA (100 mg/m2/day) for 6 months. The response was qualified
as: (a) complete remission maintained for at least 2 years (CR); (b)
modification of the response towards responsiveness to steroids (RS); or
(c) persistence of steroid-resistance (SR). Response to CFM (N = 42): 5
CR (4 MC, 1 FSGS), 14 RS (12 MC, 2 FSGS), 23 persistent SR (7 MC, 12
FSGS, 4 DMP). Response to CsA (N = 16): 8 CR (4 MC, 1 FSGS, 3
DMP), persistent SR 8. Conclusion: Under the sequential immunosup-
pressive protocol and after a follow-up period ranging from 16—169
months (.s = 63 m), the current situation of the 42 children is: 19 (45%)
complete remission, 8 (19%) relapsing steroid-responsive, and 15 (36%)
persist as steroid-resistant, 9 of whom have developed chronic renal
failure.
Predictive factors of delayed renal allograft function (DAF). Influences
of secondary hyperparathyroidism (HPT). M. Cid, JJ. Cubero, F. Cara-
vaca, IF. Espárrago, MC. Garcia, F. Roncero, M. A,robas, J.L. Pizarro, and
E. Sanchez Casado, Service of Nephrology, Hospital Infanta Cristina,
Extremadura University, Badajoz, Spain. DAF is frequent after kidney
transplantation, has a deleterious effect on graft function, and masks acute
rejection. Increased levels of PTH have been implicated as a possible
cause of DAF. We studied 70 kidney transplants in 69 patients; one was
excluded due to arterial thrombosis (40 males, 28 females, aged 41.9
12.9). DAF was defined as anuria/oliguria and/or no decrease of creatinine
levels at 48 hours. Immunosuppression consisted of cyclosporine, azathio-
prine and prednisone. We analyzed the classic factors that have an
influence on DAF. Blood samples of PTHi (IRMA Nichols Institute) were
obtained previous to renal transplant. Univariate and multivariate logistic
regression models were used as statistical analysis. Of 69 cases, 46 had
immediate graft function and 23 (33%) developed DAF. The recipients
with DAF had: higher donor age 46 16 vs. 32.5 16.6 (P = 0.008), and
longer duration of end-stage renal disease 62.7 45 vs. 41.13 35
months. No significant differences were observed between the two groups
in recipient age, cold ischemic time, and PTH levels prior transplant (363
412 vs. 440 399). Univariate analyses demonstrated that donor age(P = 0.001), cause of death, TCE vs. AVC (P = 0.02) and duration of
end-stage renal disease (P 0.03) were predictors of DAF. The multiva-
nate logistic regression suggested that donor age, cold ischemia, and time
on dialysis are the most important predictors of DAF. Conclusions: (1)
DAF accounts for 33% of renal transplants in our experience. (2) Donor
age and duration of end-stage renal failure are the most important
predictive factors. (3) PTH levels prior transplant were not different
between patients with good initial function and DAF.
Long-term treatment with cyclosporine A (CsA) increases glomerular
synthesis of thromboxane B2 in rats. G. de Arriba, T Parra, F. GarcIa-
MartIn, J.A. Gila, M. Sánchez-Heras, and M.D. Jarillo, Hospital General
Universitario de Guadalajara, Guadalajara, Spain. Chronic treatment with
CsA increases urinary excretion of thromboxane B2 (TXB2). However, it
is not known if glomerular cells contribute to the synthesis of urinary
TXB2. Our aim was to evaluate synthesis of TXB2 by isolated kidney
glomeruli of rats treated with CsA for a long period of time. CsA was
administered by oral cannulation to male Wistar rats for 30 days at a dose
of 30 mg/kg/day. Isolated glomeruli were obtained by a sieving technique.
Glomeruli were incubated at 37°C for 30 minutes, and TXB2 was
determined in supernatants. Isolated glomeruli of rats treated with CsA
synthesize more TXB2 (0.709 0.231 ng/mg protein, X SEM, N = 11)
than glomeruli obtained from control rats (0.235 0.044, N = 11) (P <
0.05). We conclude that glomerular synthesis of TXB2 increases signifi-
cantly in rats treated for 30 days with CsA. At least part of the TXB2
excreted in the urine of rats treated with CsA could have a glomerular
origin. Finally, glomerular synthesis of TXB2 could contribute to chronic
nephrotoxicity induced by CsA.
Hyperlipidemia in renal transplant (RxT): Epidemiologic analysis. IM.
Garrancho, C. Sanz Moreno, D. Sanz Guajardo, E. Besada, I Fernández,
and J. Botella, Hospital Puerto de Hierro, Madrid, Spain. Cardiovascular
(cv) disease is the leading cause of death in RxT patients, and hypercho-
lesterolemia is one of the most important cv risk factors. We have studied
the total cholesterol (chol) plasma level, chol HDL, chol LDL and
tryglicerides of the 172 RxT patients in our hospital. We have separated
the patients into three groups, according to the total chol level: (a) <200
mg/dl; (b) 200—280; (c) >280. We have analyzed in each group factors
which could affect the lipoproteic metabolism: sex, age, time since RxT,
total chol preRxT (cholpre), immunosuppressive drugs (IS) [prednisolone(p) + cyclosporine (c); p + azathioprine (a); p + c + a], creatinine
clearance, proteinuria, diabetes mellitus (DM), hepathopaty, hypertension
and antihypertensive drugs: frusemide, thiazides and beta blockers. Results:
N RxT chol: total HDL LDL Triglycerides
chol <200 46 (26.7%) 178 56 97 127
200—280 92 (53.6%) 241 64 146 144
chol >280 34(19.7%) 315 67 214 172
The following factors were found statistically significant (using t-test) as
predisposing to hypercholesterolemia:
p+c p+a p+c+a Age cholpre D.M.
chol <200 17.4% 52.2% 30.4% 41a 159 4.3%
200—280 27.2% 45.7% 27.1% 47aa 197° 7.6%
chol >280 14.7% 26.5% 58.8%° SOaa 213° 17.6%°
ap < 0.05
Conclusions: We found among our RxT population that hypercholesterol-
emia is common (19.7%), mainly as LDL fraction. Among the predisposing
factors to hypercholesterolemia we found immunosuppression with three
drugs (p+c+a), older age, the preRxT cholesterol level and diabetes mellitus.
Effect of acute administration of cyclosporine A (CsA) on the glomer-
ular synthesis of thomboxane B2 (TX) in rats. G. de Arriba, T Pan-a, F.
Garcia-Martin, M Sánchez-Heras, and M.D. Jarillo, Hospital General
Universitario Guadalajara, Guadalajara, Spain. CsA administration pro-
vokes a reversible decrease of glomerular filtration rate, which improves
with resumption of the treatment. The mechanism of this decrease is not
completely elucidated, although humoral factors have been implicated.
Our aim was to evaluate the effects of acute administration of CsA on the
glomerular synthesis and urinary excretion of TXB2. We treated male
Wistar rats (N = 5) with 50 mg/kg/day of CsA by oral cannulation, and
urinary excretion and glomerular synthesis of TXB2 were analyzed at 4
and 10 days of treatment.
Glomeruli Basal 4 days 10 days
TXB2, ng/mgprot 0.24 0.06 22.6 7.71° 281.9 106.57k'
°P < 0.05 vs. basal; bp < 0.05 vs. 4 days
We also observed an increase in urinary excretion of TXB2 in respect to
basal values at 4 and 10 days of treatment (P < 0.05). In conclusion, the
short-term treatment with CsA increases glomerular synthesis and urinary
excretion of TXB2. TXB2 could be implicated in the acute decrease of
glomerular filtration rate originated by cyclosporine A.
